

(7) Intervention studies in cancer and coronary heart disease.

In the preceding section we have attempted to demonstrate that psychosocial factors like stress and personality are important risk factors in the causation of cancer and coronary heart disease, and that specific personality constellations, reacting to stress, are particularly cancer-prone and coronary heart disease-prone. These relationships, although much stronger than those linking smoking to cancer and coronary heart disease, are still only correlational, and it is well-known that correlations cannot be used directly to infer causation. The best way of indicating that the relations observed are indeed causal is by some intervention method which brings to bear an experimental paradigm on the problem in question. We have attempted to do this by using methods of behaviour therapy (Eysenck & Martin, 1987) in an attempt to alter the behaviour of the cancer-prone or the coronary heart disease-prone person in the direction of our healthy Type 4. In other words, we have attempted to increase autonomous behaviour, and reduce the proband's dependence on other people, or his/her acceptance of situations which lead to negative consequences. In this section we will give a brief discussion of the methods used, and then go on to an evaluation of the effects of using these methods in a prophylactic manner. (For a more general discussion of prophylactic methods, see Aeberhardt, 1989.)

The therapy developed by us contains many features which are familiar, such as Wolpe's method of desensitization, Lazarus's development of coping mechanisms, social skills training, and others. The method has been called 'Autonomy Training', or 'Creative Novation Behaviour Therapy'. The major aim of the treatment is to stimulate

2023136812

an individual to look towards the long-term positive results of different types of behaviour and self-evaluation (Grossarth-Maticek & Eysenck, in press). Thus it is the aim of the treatment to increase behaviours which lead to long-term positive consequences, even though this may involve some short-term negative consequences. Conversely, the patient should learn to avoid behaviours which lead to long-term negative consequences, even where these may be associated with short-term positive consequences.

Having briefly described the methods of prophylactic behaviour therapy, we must now consider their application to a variety of probands of Types 1 and 2, i.e. people prone to cancer and coronary heart disease respectively. Three major studies have been done by us, using respectively long-term individual therapy, group therapy, and bibliotherapy conjoined with short individual therapy. These studies will be discussed with respect to death, cause of death (as shown on the death certificate) and incidence, i.e. the diagnosis of cancer or coronary heart disease made by the patient's physician, and ascertained with the prior permission of the patient. All the studies were carried out in Heidelberg (West Germany), and the therapist in each case was Professor Grossarth-Maticek who originated the methods used.

Probands in the first of these studies, using long-term individual therapy, were 100 individuals, half male, half female, who were categorized as Type 1 (cancer-prone) on the basis of interview and questionnaire data. Their mean age was around 50 years. The second group of 92 individuals, similarly selected, but all of Type 2, were chosen to study the effects of behaviour therapy on coronary heart disease. The therapy consisted of roughly 30 hours of individual therapy, as outlined at the beginning of this chapter.

2023136813

The results are shown in Table 10. It will be seen that both for cancer and for coronary heart disease, the number of deaths is very significantly less for the therapy group than for the control group. The same is true for incidence which is roughly half in the therapy group as compared with the control group. These figures suggest very strongly that behaviour therapy can prevent death from cancer or coronary heart disease, or at least postpone it for a very considerable period of time. It is of course possible that the surviving members in the therapy group will ultimately die of cancer or coronary heart disease, or at least some of them will; only a much longer follow-up, until all the participants of the study are dead, can answer this question. What we do see is that 13 years after the initiation of the study, many more members of the therapy group are alive than of the control group.

Table 10 here.

It should also be noted that details of all probands were transmitted to two independent observers prior to ascertaining death and cause of death, or incidence, in each case. In addition, a random sample of interviewers was interviewed by an independent observer to check on the collection of interview and questionnaire data. These precautions were taken as a routine measure to certify the objectivity of the data collection.

Our second study is concerned with group behaviour therapy. In this case, groups of between 20 and 25 probands were formed, and administered group behaviour therapy for periods of between six and twenty-five hours, each group meeting lasting between two and three hours. Duration was determined by the members of the groups themselves, and hence varies to a considerable degree. Matching was

2023136814

carried out as before, and members of the group were followed up over an 8-year period. Results are given in Table 11.

Table 11 here.

It will be seen that group therapy, very much like long-term individual therapy, benefitted the therapy group, as compared with the control group, by reducing the mortality from cancer and coronary heart disease, and decreasing the incidence. Given the relative unreliability of diagnoses as recorded on death certificates, the most impressive figure perhaps is that of the proportion still living, which indicates the power of behaviour therapy to prevent cancer and coronary heart disease. Again the procedure, including all the death certificates, was checked by an independent observer.

Our third study was concerned with a special kind of bibliotherapy, which centred on a text entitled: "How to Achieve Emotional Independence and a Healthy Personality". This text was introduced to participants in an hour long introduction by Professor Grossarth-Maticek, who also outlined the application of the principles contained therein to the individual proband. After a week or so to give the proband time to read and understand the text, and try to apply it to his/her own condition, specially trained students went to discuss this application of the message contained in the text to the individual's circumstances, for three one-hour periods. What we are dealing with here, then, is not just bibliotherapy, but in addition some four hours of individual therapy.

In this study the therapy group was constituted of 600 probands, matched as before with a control group of 600. Again probands were allocated on a chance basis to therapy or control. Within the control group, a small group of 100 was exposed to a placebo

2023136815

treatment, i.e. using a psychoanalytic text outlining Freudian ideas concerning the origins and prevention of cancer. Table 12 shows the results of the study. It will be seen that the placebo group does not differ significantly from the control group, but the therapy group is superior to the control group both with respect to smaller number of deaths from cancer and coronary heart disease, and lower incidence of these two diseases. The data show that even a relatively short-term application of behaviour therapy, together with bibliotherapy, can have a marked effect on mortality and incidence of cancer and coronary heart disease.

Table 12 here.

More detailed information concerning these studies is given by Eysenck (1988a, b; 1989; Grossarth-Maticek, Bastiaans, and Kanazir, 1985; Grossarth-Maticek, Eysenck & Vetter, 1988; Grossarth-Maticek, Schmidt, Vetter & Arndt, 1984). These communications also contain information on the possibilities of prolonging life even after terminal cancer has been diagnosed. It seems that the use of behaviour therapy can delay deaths from cancer and almost double the duration of survival.

It is sometimes said that the results of behaviour therapy in cancer and CHD, either prophylactically or in prolonging life, are too good to be true, yet there is much outside evidence for the efficacy of different types of psychological therapy on cancer and CHD, some of which reports results even better than those described above. To take only the most recent study, Spiegel et al. (1989) was able to double the life expectancy of female patients with metastatic breast cancer, a result even better than similar studies reported by us (Eysenck,

2023136816

1988a, b). In Spiegel et al's control group, life expectancy was 18.9 months, while in the therapy group it was 36.8 months. Such findings should be seen in the context of studies looking at the influence which psychosocial factors and interventions have on the immune system, which presumably mediates the effects of life-events, stress and therapeutic psychological intervention, and the occurrence and rigour of cancer. Before turning to a consideration of this evidence, it may be useful to consider studies suggesting the possibility of prophylactic intervention in coronary heart disease-prone probands.

Johnston (1989) has reviewed the literature in a very critical spirit, but concludes that the evidence for the view that stress management may reduce coronary heart disease through the lowering of a large number of stress related risk factors by moderate, or even small, amounts "is patchy, but a much stronger case can be made than would have seemed possible only ten years ago". (p. 277.) The cautious optimism of this quotation is mainly based on the contributions of Friedman (1987), Friedman et al., (1984, 1986), Gillet et al. (1985), Lovibond et al. (1986), and Patel et al. (1985); most convincing are the data presented by the recurrent coronary prevention project. If the results are less striking than those reported by Grossarth-Maticek, Eysenck & Vetter (1988), this may be due to the fact that the validity of the Type A concept is probably much lower than that of the Grossarth-Maticek Type 2, i.e. the coronary heart disease-prone type (Booth-Kewley & Friedman, 1987). It is also noteworthy that the theory linking stress with cancer, and stress-reduction with cancer survival, has been elaborated much more convincingly (through the innervation of the immune system) than can be said of the relation between stress and stress management, and coronary heart disease.

2023136817

Bennett & Carroll (1990) similarly conclude a review of the evidence by saying that stress management techniques "not only reduce individual risk factors, they can also reduce mortality and morbidity to CHD." (p.1.) They also conclude that "risk factors combine multiplicatively, and small decreases on a number of risk factors may reduce the risk of CHD more than if only one risk factor is targeted (Johnson, 1989; Perkins, 1989), as in most medical interventions." (P.81.) These conclusions are very much in line with our own studies.

Finally, we may quote the conclusions drawn by Taylor (1990) in his review of Health Psychology: "Research that examines whether or not psychological and social factors are involved in health and illness has largely made its point..... Investigations have addressed the direct impact of stress and other psychological states on physiological processes, the impact of psychological and social factors on risky health practices, and the impact of psychological and social factors on how people respond to potential illness states, such as whether or not they engage in appropriate illness behaviour. As such, the field has advanced to an unprecedented level of complexity in research investigations... Health psychology affords the opportunity to look beyond particular disorders to the broad principles of thought and behaviour that cut across specializations of diseases or problems studied to elucidate more fundamental psychosocial mechanisms." (p.46.)

Some of the resulting complexities are illustrated in the work of Brown & McGill (1989) and Scheier et al. (1989). The importance of optimism in the recovery of patients from coronary artery disease bypass surgery was highlighted by Scheier et al., demonstrating again the interaction of psychological states, personality and medical

2023136818

illness of recovery. Brown & McGill demonstrated the complex interaction of personality traits like optimism, which is closely linked with extraversion (Eysenck & Eysenck, 1985) and stress.


Positive life events are generally believed to have beneficial effects on health, but apparently this is only true when probands have a positive self-concept (optimism). Brown & McGill (1989) outline an identity disruption model of stress, which holds that an accumulation of life events that are inconsistent with the self-concept leads to illness. Thus positive life events in probands with a negative, pessimistic self-concept were predicted (and found) to predict the development of illness over time. Clearly, over-simplified concepts of "stress" may lead to erroneous predictions, and may account for many failures to replicate in the literature.

The findings of Brown & McGill find support in an experimental study by Brebner (1990) who showed that introverts tend to generalize experiences of failure, extraverts experiences of success, thus developing pessimistic or optimistic personality traits. Brebner considers such generalization of failure experiences as an important form of stress, but of course it is not usually mentioned in traditional stress inventories. It is noteworthy that the characteristics of cancer-prone probands agree to a considerable extent with those of introverts, while CHD probands tend to show more the characteristics of extraverts (Eysenck, 1990). These apparent relationships between predisposition to disease and well-established personality types are well worth following up along theoretical and experimental lines.

A brief outline may here be given of the way the connection between personality/stress and disease may be mediated by hormonal and physiological factors. A more detailed outline is given elsewhere.

2023136819

(Eysenck, 1986). The figure below illustrates the assumed causal pathway. Personality (Type I) and stress combine and interact to produce feelings of helplessness, hopelessness and depression; these in turn produce hormonal and other reactions of which cortisol is here given as the representative (others are the endogenous opiates, ACTH, etc.). These in turn produce immune deficiency, which allows budding cancers to develop. The well-established fact that immune reactions can be conditioned along classical lines suggests one possible way such reactions may be learned. (Ader & Cohen, 1975; Solvason, Ghanta & Hiramoto, 1988.) There is a good deal of evidence to support such a model.



The model owes much to a similar one by Solomon (1987, in press; Solomon & Moos, 1964; Solomon, Levine & Kraft, 1968) who has argued powerfully for the concept of an "immunosuppression-prone" personality (Solomon, 1985). Having surveyed the literature, he produced first 35, and later another 30 postulates, many of which are relevant to our discussion. The main postulates of interest here are given below, numbered in sequence.

2023136820

Solomon's Postulates, 1987.

1. Enduring coping style and personality factors (trait characteristics) should influence the susceptibility of an individual's immune system to alteration by exogenous events, including reactions to events. (Thus, an "immunosuppression prone" behavioral pattern is hypothesized.)
2. Emotional upset and distress (state characteristics) should alter the incidence, severity, and/or course of diseases that are immunologically resisted (infectious and neoplastic) or are associated with aberrant immunologic function (allergic and autoimmune).
3. Severe emotional disturbance and mental dysfunction should be accompanied by immunologic abnormalities.
4. Experimental behavioral manipulation (for example, stress, conditioning) should have immunologic consequences.
5. Experimental manipulation of appropriate parts of the central nervous system should have immunologic consequences.
6. Hormones and other substances regulated or elaborated by the central nervous system should influence immune mechanisms.
7. Biochemical and functional similarities might be expected between the substances modulating the function and reactivity of the

2023136821

central nervous system (neuropeptides) and the substances with comparable effects on the immune system (cytokines).

8. Behavioral interventions (such as psychotherapy, relaxation techniques, imagery, biofeedback, and hypnosis) should be able to enhance or optimize immune function.
9. Altered CNS neurotransmitter receptor site sensitivities felt to be associated with mental illnesses should be reflected in lymphocyte receptors.
10. The "functional" modes of expression of CNS and immune system should be similar.

Linn, Linn & Jensen (1981) have shown that stress and anxiety are associated with depressed immunological response. Levy et al. (1985, 1987) found that natural killer (NK) cell activity in breast cancer patients was strongly correlated with psychosocial stress indicators which accounted for 51% of the baseline NK activity variance. Warburton & La Via (1987) found that tendency towards avoiding stress was the best predictor of immunocompetence. Green and Green (1987) reported that relaxation increases salivary immunoglobulin A<sup>1</sup>. Bandura et al. (1988) found that perceived self-efficacy in exercising control over cognitive stressors activated endogenous opioid systems. Kiecolt-Glaser et al. (1984) found that distressed and lonely probands had significantly higher cortisol levels and a lower level of natural killer cell activity. Glaser et al. (1986) discovered stress-related impairments in cellular immunity, and Glaser & Kiecolt-Glaser (1985)

2023136822

found that even "relatively mild stress" depressed cellular immunity in healthy adults. Kiecolt-Glaser et al. (1984) found that high scorers on stressful life events and loneliness had significantly lower levels of NK cell activity. Herberman (1988), Irwin, Vale & Britton (1987), Nemeroff et al. (1984) and Rou et al. (1988) found impaired immune reaction in depressed groups, and Linn, Linn & Klimas (1988), Arnetz et al. (1987), Glaser, Kiecolt-Glaser, Speicher & Holliday (1985) and Shavit et al. (1989) found impaired immune reactions to stress. Jemmott and Magloire (1988) found that stress lowered salivary concentrations of S-IgA, while social support increased them. Grossarth-Maticek and Eysenck (1989) found that behaviour therapy significantly increased the percentage lymphocyte count in terminally ill women suffering from cancer, and also increased their survival time. Pennebaker et al. (1988) found that self-disclosure improved cellular immune functioning. Kiecolt-Glaser et al. (1985) found an enhancement of immunocompetence by relaxation and social contact.

Irwin, Daniels, Bloom, Smith and Weiner (1987) have shown that life events can cause depression, and reduce the effectiveness of the immune function. Similarly, Murphy, Monson, Sabol and Leighton (1987), in a prospective study of 1003 adults, found a significant correlation between depression and mortality. Rodin (1980, 1986) showed that appropriate psychotherapy reduced depression and cortisol level through psychotherapy. Dabbs and Hopper (in press) showed that cortisol level correlated with anxiety, depression and high heart rate.

Finally, the relationship between mood and the immune system response has been established in a series of studies (e.g. Baker, 1987; Dillon and Baker, 1985; Linn, Linn & Jensen, 1984; McClelland et

2023136823

all., 1989, 1985; Morgan, 1989, and Stone et al., 1987). Animal studies, too, have contributed to the formulation of the model (e.g. Glaser et al., 1985; Landenslager et al., 1983; Borysenko and Borysenko, 1982; and for a review, Justice, 1985.)

The studies quoted are only among the most recent; for reviews of the older and perhaps less convincing material the following are suggested: Jemmett and Locke (1984), Miller (1983, 1985), Baker (1987), Kennedy et al. (1988), Testima (1986), Pletnikoff, Faith, Murgo and Good (1986), Korneva, Klimentov and Shkhinek (1985), Antoni (1987) and Steptoe (1989). Taking all the published data together, they do seem to support the sort of model suggested by Dilman and Ostronmova (1984) and Eysenck (1986), and briefly outlined above. There is evidence that (1) personality and stress produce immunodestructive substances in the bloodstream; (2) that these substances do have such an immunodestructive function, and that (3) behavioural manipulations can reverse this process. Thus there appears to exist at least a preliminary model to explain along causal lines the effectiveness of behaviour therapy in prophylaxis for cancer, and in prolonging life in cancer sufferers.

There is one apparent objection to this argument. As Zanderman, Costa and McCrae (1989) have shown, there is no evidence in a nationally representative sample for any correlation between depressive symptoms and cancer morbidity. The answer to this is very simple. Depression is a multi-faceted set of symptoms, like fever, which may have diverse causes and relate to different disorders; the difference between reactive and endogenous depression is perhaps the best known. The type of depression referred to in our theory is sub-clinical, and might be defined as "hopelessness depression" (Alloy, Abramson, Metalsky and Hartlage, 1988). This concept is largely based

2023136824

95

on the work of Seligman (1975) and Abramson, Seligman and Teasdale (1978), and is essentially a cognitive diathesis-stress theory of depression (Alloy, Clements and Holden, 1985). According to this theory, "a proximal sufficient cause of depression is an expectation that highly desired outcomes are unlikely to occur, or that highly aversive outcomes are likely to occur, and that no response in one's repertoire will change the likelihood of occurrence of these outcomes." (Alloy et al., 1988 p.7.) It is in this sense that the term has been used in our research. Other varieties of depression may or may not be relevant, and it is important to note that animal work too has emphasized the importance of differentiating between escapable and inescapable shocks, and the vital contribution of predictability (Miller, 1981.)

As far as coronary heart disease is concerned there is less material to review, but sclerosis is an obvious intermediary. Grossarth-Maticek and Eysenck (in press) have reported a study in which 100 cancer-prone and 92 coronary heart disease-prone probands had the degree of sclerosis in the fundus of the eye measured on a 3-point scale by a leading ophthalmologist; before and after therapy (for a randomly selected 50% of probands in each case) and at similar points of time for probands in the control group. Fig. 7 shows the results. Type 2 probands have significantly higher levels of sclerosis than Type 1 probands, and the therapy group a significantly lower degree of sclerosis; more so for CHD-prone Type 2 than for cancer-prone Type 1 probands. This experiment is in urgent need of replication.

Fig. 7 here.

2023136825

It is of course necessary to preserve caution in interpreting these results. As in the case of epidemiology generally, there are no singular causes producing single results. Thus Cobb and Rose (1973) showed that air traffic controllers have a higher incidence of hypertension than controls, and produce the condition at a younger age. This could be interpreted as a direct effect of the greater stress under which air traffic controllers work. However, hypertension is strongly related to alcohol consumption in air traffic controllers (De Franks, Jenkinson & Rose, 1987). It is possible that the drinking may be the important determinant, as alcohol intake is known to raise blood pressure (MacMahn, 1987.). Complications of this kind are the rule in this field, rather than the exception.

Clearly the Grossarth-Maticek and Eysenck data concerning the prophylactic effects of behaviour therapy for cancer and coronary heart disease are equally subject to this caution. We have shown (Grossarth-Maticek, Eysenck, Gallasch, Vetter and Frentzel-Beyme, in press) that after therapy there is a very significant shift from Type 1 or Type 2 behaviour to Type 4 behaviour; there is no change in smoking habits. However, as Pearl (1925) has pointed out, there is a style of life which embraces many different behaviour patterns, and changing one may change many others, one of which, or any combination of which, can carry the burden of changes in cancer-proneness or coronary heart disease-proneness. We are only at the beginning of the scientific study of these complex nomological networks, and should not pretend to a greater or more secure understanding of these causal effects than is reasonable under the circumstances.

Eysenck (1989) has discussed the social implications of this type of work. Clearly preventive medicine is much more humane in its consequences, as well as much cheaper, than traditional medicine which

2023136826

waits until the disease has manifested itself before attempting any intervention. Many practical, social and ethical problems are raised when we consider the possibility of introducing methods of this kind for the prevention of cancer and coronary heart disease into the social systems at present concerned with health, but it is time that the issues were taken seriously, and debated in a meaningful fashion. These issues are too serious to be left to epidemiologists.

What is most important from the point of view of this book, of course, is the demonstration of the heightened probability of a causal relation between stressed personality, on the one hand, and cancer and coronary heart disease, on the other. The failure to demonstrate such a relationship between smoking and disease, shown in previous sections, is the most vulnerable point in the orthodox view. These results show that it is possible to demonstrate causal relations following accepted scientific methodology, and to establish personality and stress as important risk factors in cancer and coronary heart disease.

2023136827

(8) Summary and Conclusions.

In spite of all the criticisms that may justifiably be made of modern epidemiological methods and findings, it is possible to make some fairly definitive statements which characterize the present status of research in the field covered by this book.

(1) It is clear beyond doubt that there is a debate going on concerning risk factors in cancer and coronary heart disease, particularly smoking. On the one hand we have a large group of physicians, epidemiologists and others who claim that smoking is the major cause of cancer and coronary heart disease, and that if only we could stop people smoking large numbers of lives could be saved. On the other hand we have a large number of physicians, epidemiologists, oncologists and other scientists who believe that what we are dealing with is a multiplicity of risk factors, interacting in complex ways, of which smoking is only one, and not by any means the most important. The Press has almost entirely suppressed representation of this alternative view, and has given rise to the completely unjustified and unscientific belief that smoking is the main and almost the only risk factor for cancer and coronary heart disease. It seems about time that the truth regarding the existence of this debate was publicly acknowledged, and that the irresponsible exaggerations concerning the effects of smoking ceased to be published and broadcast.

(2) There is now little doubt that smoking has certain positive effects which account for its popularity, and the curious fact that even people who believe that smoking causes disease still continue to smoke. Among the positive features of smoking which have now been firmly established by research are its ability to raise the cortical

2023136828

arousal level, and thus counteract boredom and fatigue; its ability to make anxious and tense persons relax, thus reducing the impact of negative emotions; and its power to increase attention and vigilance, thus enabling people to work longer and harder, and more efficiently, than they could do otherwise. These are important advantages, which should be set against the disadvantages of smoking. There does not seem to be any truth in the allegation that smoking is an addiction, even if that term could be defined in such a way as to have a scientific meaning. People maintain the smoking habit because of the positive effects of smoking on their psychological wellbeing; if we substitute alternative behaviours which serve the same needs, smoking can readily be given up as being no longer required.

(3) The relative importance of smoking as a risk factor, compared with psychosocial and other risk factors, has received a good deal of attention. Roughly speaking it would appear that personality and stress are 6 times as important as smoking in the statistical correlation between disease and risk factors. This does not mean that smoking is necessarily harmless, but it certainly puts into perspective its possible influence on cancer and coronary heart disease.

(4) What emerges with particular clarity from all the work that has been summarized in these pages is the importance of psychosocial factors, i.e. stress and the individual's reaction to stress. Of all the risk factors considered, this is perhaps the most important, showing the strongest correlation with death from cancer and coronary heart disease. It is curious, considering the long history of theories concerning psychosocial factors, going back for over 2,000 years, that the medical profession has on the whole failed to pay much attention to the importance of stress and personality in the causation

2023136829

of disease, and tends to reject claims that stress is a real killer. The evidence is too strong now to reject such claims out of hand.

(5) The only model which is remotely adequate to contain the known facts in this field is a multifactorial synergistic model, i.e. one in which many risk factors are included, and where these risk factors act in a synergistic, (i.e. multiplicative), rather than in an additive fashion. Thus in our own work smoking has always been found to be uncorrelated with cancer or with coronary heart disease in groups where there was no stress, or where a healthy personality counteracted the stress and managed to cope with it. Positive correlations with disease do appear in populations of Type 1 or 2, i.e. populations where stress is endemic, and coping behaviour is inadequate.

(6) So far we have discussed only correlations between risk factors like smoking, stress, personality, etc., and disease; it is well known that correlation does not imply causation, and that statistical association may suggest but does not prove causation. The best demonstration that a causal model may be indicated is furnished by intervention studies. If we believe that smoking causes cancer and coronary heart disease, then clearly quitting smoking should reduce the risk of cancer and coronary heart disease. As we have shown, the evidence does not suggest that this is so. Where quitters are self-selected, they already differ profoundly in their state of health from continuing smokers, and any differences in outcome are more likely to be due to this difference than to the effects of quitting. Where quitters are part of a therapy group, their future health does not, or only slightly, differ from that of continuing smokers. The evidence is confused at best, but it certainly does not support the wildly excessive claim that has been

2023136830

made for the beneficial effects of quitting smoking.

(7) The position is quite different with respect to psychosocial factors, where the evidence now seems conclusive that the application of the methods of behaviour therapy to people suffering from stress and inadequate coping mechanisms can prevent cancer and coronary heart disease, when groups receiving such help are compared with groups not receiving it. Thus not only are psychosocial factors statistically much more closely related to disease, but there is evidence for a causal influence here which is absent in the case of smoking.

(8) Clearly there must be intermediary factors intervening between stress and personality, on the one hand, and disease, on the other, and the discovery of such factors is one of the major tasks for future research. It seems reasonable to assume that the major intermediary in the case of cancer is the immune system, and there is evidence that behaviour therapy can improve the efficacy of the immune system, while stress has the opposite effect (Eysenck, 1986; Rodin, 1984, 1986). Similarly, there is evidence for a marked influence of stress and behaviour therapy on the degree of sclerosis shown by individual probands (Grossarth-Maticek et al., in press). With this whole field of research being so young, this area has not been sufficiently researched to come to any very definite conclusion, but these are suggestions which are certainly worth following up.

It would not be right to pretend that the position in which we find ourselves is a very comfortable one, or that our knowledge is anything like as adequate to the challenges of disease as it ought to be. One of the major reasons for this unsatisfactory position is that research money has gone into areas which have proved unrewarding.

We may with advantage remind ourselves that the Multiple Risk

2023136831

(9) Epilogue.

The question of risk factors for cancer and coronary heart disease, and the relative importance of smoking as a risk factor, is clearly an important scientific problem which should be solved by the use of traditional scientific methods. Yet we have found that conclusions have often been based on inadequate methodology, doubtful assumptions, inappropriate statistics, and inadmissible extrapolations. It seems that evangelical fervour, dogmatic certitude and propagandist intentions have only too often led to a premature crystallization of spurious orthodoxies which has set back the factual study of the subject and delayed the finding of proper answers by many years. It is unfortunate that the issue has become clouded by an anti-smoking crusade which pays scant regard to the facts of the case, but uses facts selectively to prove a conclusion already predetermined on a priori grounds.

In this the whole controversy resembles similar controversies which have ranged around issues like the role of cholesterol in CHD, or that of fluoridation of the water supply. In both cases, publicity campaigns were waged in order to get people to substitute margarine for butter, change the whole diet to lower cholesterol levels, increase the fluoride level of the water supply, and quite generally change people's habits in line with supposititious benefits to their health. Had these benefits been real, and had these changes in fact produced better health and longer life, the fanatical support given these measures might be understandable. However, as already noted, there do not seem to be any obvious benefits to be derived from a

2023136832

cholesterol-low diet, and in fact it might be linked with increasing risks of cancer. Similarly, fluoride in the water supply is now stated to provide little if any benefit as far as tooth decay is concerned and may indeed have the opposite effect. Furthermore, it has been suggested that it may be linked with increasing risks of cancer.

I cannot pronounce on these developments as far as their medical background is concerned; the new developments may have as little substance as the old. They may, however, have the beneficial effect of making lay readers, and possibly even medical readers, less prone to take seriously any pronouncements of epidemiological "experts" based on insufficient evidence and grossly defective studies. What is being criticized is not the individual scientist who draws the wrong conclusion from his data, or who commits errors of one kind or another in his experimental methodology, or his statistical analysis. To err is human, and all scientists are prone to blunders of one kind or another.

But scientists should be modest in their claims, should refuse to exaggerate the certainty of their conclusions, and should always be open to correction and the consideration of contrary evidence. In particular, they should refrain from advocating far-reaching social actions on the basis of doubtful, fallible, disputed and insufficient evidence. Equally, they should not pretend that contradictory data do not exist, that anyone who doubted the correctness of their arguments was acting on improper motives, or that it was irresponsible to argue against their firm convictions. Yet the propounders of the low cholesterol diet, and the advocates of fluoridation, have been guilty of all these misdemeanours, as have those who have condemned cigarette-smoking out of hand as being responsible for the majority of

2023136833

deaths from cancer and CHD.

Here, as with cholesterol and fluoride, scientists have been guilty of suppressio veri and suggestio falsi, of neglecting to inform the public of facts contrary to their beliefs, of public statements going way beyond the established facts, of emotional propaganda not based on solid evidence, and altogether of fanatical publicity-seeking quite alien to the received model of the genuine scientist. There is no culpability in being wrong, but there is culpability in perpetuating error in the face of contradictory evidence, in bigoted and zealous over-enthusiasm, and in prematurely urging major social intervention on the basis of doubtful and contradictory evidence.

The grossly exaggerated claims concerning the degree of risks attending cigarette smoking in the causation of cancer and CHD must stand with the grossly exaggerated claims concerning cholesterol and fluoride as a warning to scientists to avoid jumping on bandwagons, join publicity campaigns, or advocate premature social action. As Claude Bernard warned a hundred years ago: "In ignorance, abstain!"

There is one additional matter that requires discussion in this context. The premature claims for the preventive possibilities of a reduced cholesterol diet in relation to CHD, fluoridation in relation to tooth decay, and giving up smoking in relation to cancer and CHD, and the widespread publicity these have received through the media, have suggested to the layman that a far greater certitude attends to these claims than can be justified scientifically, as we have seen. The recent findings that these claims are in fact unfounded, and that fluoridation, or indulgence in a low cholesterol diet may in fact harm rather than benefit the individual, have led to bewilderment, and a feeling, only too well justified, that "expert" opinion on medical

2023136834

matters is quite untrustworthy, and that the constant reversals of recommendations for a healthier living emanating from such sources indicate a lack of true knowledge, and a partisanship unworthy of scientists. As Le Fanu (1987) has pointed out, in the 30s we were advised by nutritionists to eat more eggs and butter, and drink more milk. A few years later all these nutriments became anathema, in the interests of a low cholesterol diet. Now we are being told that this was all a mistake, and that there is no harm in eggs, butter and milk, and that they may even be good for us. Clearly something has gone wrong very badly when violently opposite recommendations are made on the apparent basis of "scientific" evidence, and the public has a right to be bewildered, and to doubt if such advice is really based on fact rather than passing fancy. This undermines public faith in the objectivity of science, and the truth-value of scientists' published beliefs; it is, indeed, the old story of the boy who cried 'Wolf'. Having cried wolf so often, only to retract the statements of the alleged danger, nutritionists, epidemiologists and other medical specialists are now in danger of being disbelieved even when their warnings are only too well justified.

Worse yet, warnings which are not justified by the state of our present knowledge may themselves increase stress, and lead to very serious health consequences. Our study (Grossarth-Maticek & Eysenck, 1989) has shown that such fears are indeed only too real, and that the constantly repeated media threat that smoking kills has in fact become a self-fulfilling prophecy! Thus the lack of responsibility shown in making publicly unjustified statements about the evil consequences of smoking is underlined by the actual consequences of making such statements, namely the deaths of numerous people frightened literally out of their lives by the media and their grossly and very partial

2023136835

accounts of the evidence (Clark, 1989). When the assertions made by apparently authoritative bodies and persons, such as the Royal College of Physicians or the Surgeon-General of the United States, grotesquely exaggerate the consequences of smoking in deaths from cancer and CHD, and the virtues of giving up smoking, it is small wonder that the media, as well as politicians, take up the chorus, not realizing that there is little justification for the claims made, and that they have received damaging criticism from leading oncologists, immunologists, and other scientists.

The only responsible way out of this practice, which is seriously embarrassing for medicine and science alike, is to return to the precepts which have always guided science in the past. Publications should contain not only assertions of position, based on selected and biased evidence, but should deal fairly and squarely with all objections, criticisms and contrary findings. Conclusions should be justified by the evidence, and carefully qualified rather than extreme in their certainty when this is not warranted. Finally, no publicity should be given to results, and no publication urged or taken, unless there is virtual agreement among experts (as there most certainly is not in relation to the effects of smoking) about the issue in question. Even then the fallability of research in such very complex areas should be emphasized, and the possibility of error acknowledged. These are the ways science has progressed, and has acquired its unique prestige; we should be careful not to squander it in the way that it has been squandered in relation to these controversies.

What is particularly to be regretted is the intrusion of political associations into scientific debates. It is interesting to note that one of the most determined protagonists of the "smoking causes disease" view, (Everett Koop, the former U.S. Surgeon-General)

2023136836

has recently been condemned by a House of Representative Committee for suppressing evidence on another issue, also involving social and ethical considerations, namely abortion. According to the Committee, Koop refused to publish a study of the physical and psychological effects of abortion on women, because the study found no evidence that the procedure harms women. At least one scientist working at the U.S. Government's Center for Disease Control, whose research focused on abortion, had his findings censored, and another was demoted, according to the Committee. Apparently when the Report commissioned by the White House had failed to provide the hoped-for evidence condemning abortion, "he therefore decided not to issue a report, but instead to write a letter to the president which would be sufficiently vague as to avoid supporting the pro-choice position that abortion is safe for women." Federal funding of research on contraception had halved since 1980, Government officials often treated those who did research on abortion with hostility, and officials who did not obey the anti-abortion line and dared to contradict Koop were fired or transferred, and their writing censored.

These are precisely the tactics that have been used widely in connection with the "smoking causes disease" issue. It has become difficult for those who wish to examine the problem objectively to obtain research funds, or to publish their data, if they are not in line with official policy. Newspapers refuse to discuss the facts objectively, and pretend that unanimity exists when in reality confusion reigns, and criticism of the "orthodox" view is widespread. Alternative models are dismissed without proper examination, and are never mentioned in official publications. Investigators who show an interest in such models encounter obstacles in their careers, and may have all support withdrawn, regardless of the quality of their

2023136832

research. These are not conditions which encourage high-class scientific research, and it is small wonder that the field is confused and full of anomalies. In this book I have tried to set out the facts as carefully and objectively as possible, and to point out the major conclusions which may be drawn.

The failure of many workers in this field to be objective, and to tell the public fairly and squarely about the present position of research, has been exposed most convincingly by Effron (1984) in her book on "The Apocalyptic", which cuts a much wider swathe than the present book, but which justifies amply its subtitle: "Cancer and the big lie". It deals with "the ideological corruption of cancer research in the United States." The author contends, and demonstrates, that an extreme environmental movement, which she calls "the apocalyptic", has politically distorted research in environmental cancer, saturating the United States with theories of cancer that are pure myths. Her book should be read by all concerned with the problem of cancer origin and propagation; the problem considered in this book is only one facet of this much wider phenomenon. There is no doubt that smoking is one of many risk factors in cancer and CHD, but the notion that it is all-important, and that reduction in smoking would have far-reaching benevolent consequences as far as cancer and CHD are concerned, is just one of those myths which Effron castigates.

There is much that remains obscure, but there are also some features of the scene which must be regarded as hopeful. If stress and other psychosocial factors are indeed killers, it does seem that suitable prophylactic means are at hand to delay or prevent cancer and coronary heart disease. Behaviour therapy is a very cheap and convenient way of safeguarding healthy probands from cancer and

2023136838

coronary heart disease, and from every point of view prevention must be better than largely non-existent cures or very expensive treatments with often disastrous side-effects. If only we could disabuse ourselves of the present unhealthy preoccupation with smoking, and turn our attention to the real enemy, namely stress, we could in reality save all those lives which a dishonest propaganda effort has tried to persuade us could be saved if only we gave up smoking. This is a serious issue, vital for hundreds of thousands of people, and it is irresponsible to continue a bland and biased disregard of the true facts of the case.

2023136839

Factor Intervention Trial Study was stated to have cost 115 million dollars, with the true cost being probably appreciably higher; yet that study was fundamentally flawed from the beginning, was badly executed and analysed, and gave results that were embarrassing to the medical profession as a whole. Had the money been spent on proper scientific research we would be very much more knowledgeable than we are now.

In particular, research is vital in the area we know least about, namely the effects of stress and of behaviour therapy on the immune system; prospective studies of the kind pioneered by Grossarth-Maticek (see references) should be repeated with the inclusion of direct measures of immune system assays, and with multiple measures of sclerosis. Only in this way will we achieve greater knowledge of the causes of cancer and coronary heart disease, and of the most efficient methods of preventing them.

2023136840

## REF E R E N C E S

Abelin, T.

Rauchen und Gesundheit. Zurich: Schweizerische Vereinigung gegen Tuberkulose und Langen Krankheiten, 1989.

Abramson, J.H., Sacks, U.I., Cabana, E.

Death certificate data as an indication of the presence of certain common diseases at death.

J. Chron. Dis., 1971, 14, 417-431.

Abramson, L.Y., Seligman, M.E.P., & Teasdale, H.

Learned helplessness in humans? Critique and reformulation.

J. Abn. Psychol., 1978, 87, 49-74.

Ader, R., & Cohen, N.

Behaviorally conditioned immuno-suppression.

Psychosom. Med., 1975, 37, 333-340.

Aeberhardt, E. (Ed.):

Bericht zur Krebsverhutung.

Winterthur: E. Aeberhardt Stiftung, 1989.

Allred, K.D., & Smith, T.W.

The hardy personality: Cognitive and physiological responses to evaluative threat.

J. Person. Soc. Psychol., 1989, 56, 257-266.

Alloy, L.B., Abramson, L.Y., Metalsky, C., & Hartlege, S.

The hopelessness theory of depression: Attributional aspects.

Brit. J. Clin. Psychol., 1988, 27, 5-21.

Alloy, L.B., Clements, C., & Kioden, G.

The cognitive diathesis - stress theories of depression:

2023136841

Therapeutic implications. In: S. Reiss & R. Bortzin (Eds.), Theoretical Issues in Behavior Therapy. New York: Academic Press, 1985.

Antoni, M.H.

Neuroendocrine influences in psychoimmunology and neoplasia: A review. Psychology and Health, 1987, 1, 3-24.

Arnetz, B., Wasserman, J., Petrini, B., Brenner, F., Levi, L., Eneroth, P., Solovaara, H., Hjelm, D., Thoerell, T., & Pettersen, I.

Immune function in unemployed women.

Psychosom. Med., 1987, 49, 3-12.

Atteslander, P. (Ed.)

Smoking and Mortality in Switzerland.

Zurich: Arbeitsgruppe Gesundheitsforschung, 1989.

Ashton, H., & Stepney, R.

Smoking, Psychology and Pharmacology.

London: Tavistock, 1982.

Aviado, D.M.

Health issues relating to "passive" smoking.

In: R.D. Tollison, (Ed.), Smoking and Society. Pp. 137-166.

Toronto: Lexington Books, 1986.

Baalen, D. van, & de Vries, M.J.

"Spontaneous" regression of cancer.

Rotterdam: Erasmus University, 1987.

Baker, G.H.B.

Psychological factors and immunity.

J. Psychosom. Res., 1987, 31, 1-10.

Banner, K., & Newberry, B.H. (Eds.).

2023136842

Stress and Cancer.

Toronto: C.J. Hogrefe, 1981.

Bandura, A., Cioffi, D., Taylor, C.B., & Brouillard, M.E.

Perceived self-efficacy in coping with cognitive  
stressors and opioid activation. J. Person. & Soc. Psychol.,  
1988, 55, 479-488.

Bauer, F.W., & Robbins, S.L.

An autopsy study of cancer patients.

J. Amer. Med. Asscn., 1972, 227, 1431-1474.

Beadenkopf, W.G., Abrams, M., Daoud, A. & Marks, R.U.

An assessment of certain medical aspects of death  
certificate data for epidemiologic study of  
arteriosclerotic heart disease.

J. Chron. Dis., 1963, 16, 249-262.

Beek, H.J. van.

Linguistic differences in the speech of cancer and CHD-patients.

Rotterdam: Erasmus University, no date.

Belcher, J.R.

World-wide differences in the sex ratio of bronchial  
carcinoma. Brit. J. Dis. Chest., 1971, 65, 205-221.

Bennett, P., & Carroll, D.

Stress management approaches to the prevention of  
coronary heart disease.

Brit. J. Clin. Psychol., 1990, 29, 1-12.

Berkson, J.

Smoking and Lung Cancer: some observations in two recent reports.

J. Amer. Stat. Asscn., 1958, 53, 28-38.

Berkson, J., & Elvebach, L.

Competing exponential risks, with particular reference

2023136843

11

to the study of smoking and lung cancer.

J. Amer. Stat. Asscn., 1960, 291, 415-428.

Berridge, V., & Edwards, G.

Opium and the People: Opiate Use in Nineteenth Century England.

New York: Yale University Press, 1987.

Booth-Kewley, S., & Friedman, H.

Psychological predictors of heart disease: A quantitative review.

Psychol. Bull., 1987, 101, 343-362.

Borysenko, M., & Borysenko, J.

Stress, behaviour and immunity: Animal models and mediating mechanisms. Gen. Hosp. Psychiat., 1982, 4, 59-67.

Brebner, J.

Personality and generalization as a source of stress.

In: J. Sarason, C. Spielberger, J. Strelau & J. Brebner (Eds.), Stress and Anxiety, Vol. 13.

Washington, D.C.: Hemisphere, 1990.

Briggs, R.L.

Quality of death certificate diagnosis as compared with autopsy findings. Arizona Med., 1975, 32, 617-624.

Brindley, D.N., & Rolland, Y.

Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis.

Clin. Sci., 1989, 77, 453-461.

Britton, M.

Diagnostic errors discovered at autopsy.

Acta Med. Scand., 1974, 1696, 203-210.

Brown, J.D., & McGill, K.L.

2023136844

The cost of good fortune: When positive life events produce negative health consequences.

J. Person. Soc. Psychol., 1989, 57, 1103-1110.

Brownlee, K.A..

A review of "Smoking and Health."

J. Amer. Stats. Asscn., 1965, 60, 722-739.

Burch, P.R.J.

The Biology of Cancer: A New Approach.

Lancaster: Medical and Technical Publishers. 1976.

Burch, P.R.J.

Smoking and lung cancer: The problem of inferring cause.

J. Roy. Stats. Soc., 1978, 141, 437-477.

Burch, P.R.J.

The Surgeon-General's "epidemiologic criteria for causality":

A critique. J. Chron. Dis., 1983, 36, 821-836.

Burch, P.R.J.

Can epidemiology become a rigorous science?

How big is The Big Kill?

IRCS Med. Sci., 1986, 14, 956-961.

Cameron, M. & McGoogan, E.

A prospective study of 1152 hospital autopsies.

Part I: Inaccuracies in death certificates.

J. Path., 1981, 133, 273-283.

Cameron, M. & McGoogan, E.

A prospective study of 1152 hospital autopsies,

Part II: Analysis of inaccuracies in clinical diagnoses

and their significance. J. Path., 1981, 134, 285-300.

Chan, W.C., Colbourne, M.J., Fung, S.C. & Ho, H.C.

Bronchial cancer in Hong Kong, 1976-1977.

2023136845

Brit. J. Cancer, 1979, 39, 182-192.

Clark, S. (Ed.).

Smoke Out: How the Quality Pressures the Smoking Debate.

London: Centre for Media Research and Analysis: 1989.

Cobb, S., & Rose, R.M.

Hypertension, peptic ulcer and diabetes in air traffic controllers. J. Amer. Med. Asscn, 1973, 224, 489-492.

Cooper, C.L.

Stress Research.

New York: Wiley & Sons, 1983.

Cooper, C.L. (Ed.)

Psychosocial Stress and Cancer.

New York: John Wiley & Sons, 1989.

Curwen, M.P. Kanaway, E.L., & Kanaway, N.G.

The incidence of cancer of the lung and larynx in urban and rural districts.

Brit. J. Cancer, 1954, 8, 181-198.

Dabbs, J.M., & Hopper, C.H.

Cortisol, arousal, and personality in two groups of normal men.

Person. & individ. Diffs., in press.

Dawber, T.R.

The Framingham Study: The Epidemiology of Atherosclerotic Disease.

Cambridge, Mass.: Harvard University Press, 1980.

Day, S.B. (Ed.)

Cancer, Stress and Death.

New York: Plenum, 1986.

2023136846

De Frank, R.S., Jenkins, C.D. & Rose, R.M.

A longitudinal investigation of the relationship among alcohol consumption, psychosocial factors and blood pressure.

Psychosom. Med., 1987, 49, 236-249.

Dembrowski, T.M.,

Stress and substance interaction effects on risk factors and reactivity.

Behav. Med. Update., 1984, 6, 16-19.

Dillon, K.M. & Baker, K.H.,

Positive emotional states and enhancement of the immune system.

Internat. J. Psychiat. in Med., 1985-86, 15,  
13-18.

Dilman, V.M., & Ostroumova, M.V.

Hypothalamic, metabolic, and immune mechanisms of the influence of stress. In: B.N. Fox & B.H. Newberry (Eds.), Impact of Psychoendocrine Systems in Cancer and Immunity.

New York: C.J. Hogrefe, 1984.

Doll, R. & Peto, R.

Mortality in relation to smoking:

20 years' observations of male British doctors.

Brit. Med. J., 1976, 2, 1525-1536.

Editorial.

Medical charities and prevention.

Brit. Med. J., 1971, 2, 1616.

Effron, E.

The Apocalyptic: Cancer and the Big Lie.

New York: Simon & Schuster, 1984.

Enstrom, J.E.

Cancer mortality among Mormons in California during 1968-1975.

2023136847

J. Nat. Cancer Inst., 1980, 65, 1073-1082,  
Eylenbosch, W.J., Depoorter, M., & Larebeke, N.V.  
Primary Prevention of Cancer, Vol. 19.  
New York: Raven Press, 1988.

Eysenck, H.J.  
Personality and the maintenance of the smoking habit.  
In: W.L. Dunn (Ed.), Smoking Behaviour: Motives and Incentives.  
Washington, D.C.: Winston/Wiley, 1973.

Eysenck, H.J.  
The Causes and Effects of Smoking.  
London: Maurice Temple Smith, 1980.

Eysenck, H.J.  
Personality, cancer and cardiovascular disease: a causal analysis. Person. & Individ. Diff., 1985, 5, 535-557.

Eysenck, H.J.  
Smoking and Health. In: R.D. Tollison (Ed.), Smoking and Society. Pp. 17-88. Lexington: Lexington Books, 1986.

Eysenck, H.J.  
Rauchen und Gesundheit.  
Dusseldorf: W. Rau Verlag, 1987.

Eysenck, H.J.  
The respective importance of personality, cigarette smoking and interaction effects for the genesis of cancer and coronary heart disease. Person. & Individ. Diff., 1988, 9, 453-464.

Eysenck, H.J.  
Behaviour therapy as an aid in the prevention of cancer and coronary heart disease.  
Scand. J. Behav. Therap., 1988b, 17, 171-188.

2023136848

Eysenck, H.J.

Type A behavior and coronary heart disease: The third stage.

J. Soc. Behav. & Person., 1990, 5, 25-44.

Eysenck, H.J., & O'Connor, K.

Smoking, Arousal and Personality. In: A. Remond & C. Izard,

(Eds.) Electrophysiological Effects of Nicotine.

Amsterdam: Elsevier/North Holland, 1979.

Eysenck, H.J., Tarrant, M., & Woolf, M.

Smoking and personality.

Brit. med. J., 1960, 1, 1456-1460.

Feinstein, A.R.

Scientific standards in epidemiologic studies of the  
menace of daily life.

Sci., 1988, December, 1257-1263.

Feinstein, A.R. & Wells, C.K.

Cigarette smoking and lung cancer: The problem  
of "detection bias" in epidemiologic rates of disease.

Transacts. Asscn. Amer. Physic. 1974, 87, 180-185.

Fisher, R.A.

Smoking: The Cancer Controversy.

Edinburgh: Oliver & Boyd, 1959.

Fleiss, J.L.

Statistical Methods for Rates and Proportions.

New York: Wiley, 1987.

Friedman, G.D., Siegelaub, A.B., Dales, L.G., & Seltzer, C.C.

Characteristic predictions of coronary heart disease  
in ex-smokers before they stopped smoking:

Comparisons with persistent smokers and non-smokers.

J. Chron. Dis., 1979, 32, 175-190.

2023136849

Friedman, M.

Effect of modifying Type A behaviour after  
myocardial infarction in recurrence rates.

Mount Sinai J. Med., 1987, 51, 47-55.

Friedman, M., Thorensen, C., Gill, J., Powell, L.,

Ulmer, D., Thompson, L., Price, V., Rabin,  
D., Breall, W., Dixon, T., Levy, R., & Bourg, E.

Alterations of Type A behavior and reduction in cardiac  
recurrence in postmyocardial infarction patients.

Amer. Heart J., 1984, 108, 237-248.

Friedman, M., Thorensen, C.E., Gill, J.J., Ulmer, D.,

Powell, L.H., Price, V.A., Brown, B., Thompson, L.,  
Rabin, D.D., Breall, W.S., Bourg, E., Levy, R., & Dixon, T.

Alteration of Type A behavior and its effect on cardiac  
recurrences in postmyocardial infarction patients: Summary  
results of the recurrent coronary heart prevention project.

Amer. Heart J., 1986, 112, 653-665.

Fries, J., Green, L., & Levine, S.

Health promotions and the comparison of morbidity.

Lancet, March 4, 1985, 481-483.

Frith, C.D.

Smoking behaviour and its relation to smokers' immediate  
experience. Brit. J. Soc. Clin. Psychol., 1971, 10, 73-78.

Gill, J.J., Price, V.A., Friedman, M., Thorensen, L.E., Powell, L.N.,  
Ulmer, D., Brown, B., & Drews, F.R.

Reduction in Type A behavior in healthy middle-aged American  
military officers. Amer. Heart J., 1985, 110, 503-514.

Glaser, R., Kiecolt-Glaser, J.

2023136850

"Relatively mild stress" depresses cellular immunity in healthy adults. Behav. & Brain Sci., 1985, 8, 401-403.

Glaser, R., Kiecolt-Glaser, J., Speicher, C., & Holliday, J. Stress, loneliness and changes in herpes virus latency. J. Behav. Med., 1985, 8, 249-260.

Glaser, R., Kiecolt-Glaser, J., Start, J.C., Tarr, K.L., Speicher, C.E., & Halliday, J. Stress-related impairments in cellular immunity. Psychiatric Res., 1986, 16, 233-239.

Glaser, R., Thorn, B.E., Tarr, K.L., Kiecolt-Glaser, J. & D'Ambrosia, S. Effects of stress on methyltransferase synthesis: An important DNA repair enzyme. Health Psychol., 1985, 4, 403-412.

Gordon, T., Kannel, W., & McGee, D. Death and coronary heart attacks in men after giving up cigarette smoking. A report from the Framingham Study. Lancet, 1974, 7, 1345-1348.

Green, R.G., & Green, M.L. Relaxation increases salivary immunoglobulin A<sup>1</sup>. Psychol. Rep., 1987, 61, 623-629.

Greer, S., Morris, T., & Pettingale, K.W. Psychological response to cancer: Effect on outcome. Lancet, 1979, 2, 785-787.

Grossarth-Maticek, R. Social psychotherapy and course of the disease. Psychother. & Psychosom., 1980, 33, 129-138.

Grossarth-Maticek, R. Synergistic effects of cigarette smoking, systolic blood pressure

2023136851

and psychosocial risk factors for lung cancer, cardiac infact and Apoplexy Cerebri.

Psychotherapy and Psychosomatics, 1980, 34, 267-272.

Grossarth-Maticek, R.

Psychosociale Verhaltenstypen und chronische Erkrankungen.

Der Kassenarzt, Sept., 1986, 39, 26-35..

Grossarth-Maticek, R.

Disposition, Exposition, Verhaltensmuster, Organsverschadigung und Stimulierung des Zentralen Nervensystems in der 'A'tiologie des Bronchial-, Magen-, und Leber Karzinoma.

Deutsche Zeitschrift fur Onkologie, 1989, 21, 62-, 78-,

Grossarth-Maticek, R., Bastiaans, J., & Kanazir, D.T.

Psychosocial factors as strong predictors of mortality from cancer, ischaemic heart disease and stroke: The Yugoslav prospective study. J. Psychosom. Res., 1985, 29, 167-176.

Grossarth-Maticek, R., & Eysenck, H.J.

Is media information that smoking causes illness a self-fulfilling prophecy? Psychol. Rep., 1989, 65, 177-178.

Grossarth-Maticek, R., & Eysenck, H.J.

Length of survival and lymphocyte percentage in women with mammary cancer as a function of psychotherapy.

Psychol. Rep., 1989, 65, 315-321.

Grossarth-Maticek, R., Eysenck, H.J., Gallach, B., Vetter, H., & Frentzel-Beyme, R.

Changes in degree of sclerosis as a function of prophylactic treatment in cancer-prone and CHD-prone probands.

J. Psychosom. Res., in press.

2023136852

Grossarth-Maticek, R., Eysenck, H.J., & Vetter, H.

Personality type, smoking habit and their interaction as predictors of cancer and coronary heart disease.

Person. Individ. Diff., 1988, 9, 479-495.

Grossarth-Maticek, R., Eysenck, H.J., Vetter, H., & Schmidt, P.

Psychosocial types and chronic diseases: Results of the Heidelberg Prospective Psychosomatic Intervention Study.

In: S. Maes, C. Spielberger, P. Defares & I.G. Sarason (Eds.),

Topics in Health Psychology. Pp. 57-75.

London: John Wiley & Sons, 1988.

Grossarth-Maticek, R., Kanazir, D.T., Schmidt, P., & Vetter, H.

Psychosomatic factors in the process of cancerogenesis.

Psychother. & Psychosom., 1982, 28, 284-302.

Grossarth-Maticek, R., Kanazir, D.T., Vetter, H. & Jankovic, M.

Smoking as a risk factor for lung cancer and cardiac infarct as mediated by psychosocial variables.

Psychother. & Psychosom., 1983, 39, 94-105.

Grossarth-Maticek, R., Schmidt, P., Vetter, H., & Arundt, S.

Psychotherapy research in oncology. In: A. Steptoe and A. Mathews (Eds.), Health Care and Human Behaviour. Pp. 325-341.

London: Academic Press, 1984.

Grossarth-Maticek, R., Siegrist, J., & Vetter, H.

Interpersonal regression as a predictor of cancer.

Soc. Sci. Med., 1982, 16, 493-498.

Grossarth-Maticek, R., Vetter, H., & Frentzel-Beyme, R.

Precursor lesions of the GI tract and psychosocial risk factors for prediction and prevention of gastric cancer.

Cancer Detect. Prev., 1988, 13, 23-29.

Gruver, R.H. & Freis, E.D.

2023136853

A study of diagnostic error.  
Annals of Internal Med., 1957, 47, 108-120.

Guberan, E.  
Surprising decline of cardiovascular mortality in Switzerland: 1951-1976. J. Epidemiol. Comm. Hlth., 1979, 33, 114-120.

Gunning-Schopers, L., Barrendregt, R., & Maas, J.  
Population interventions reassessed.  
Lancet, March 4, 1989, 479-481.

Hager, E.D. (Ed.).  
Biomodulation und Biotherapie des Krebses.  
Heidelberg: E. Fischer, 1986.

Hammond, E.C.  
Smoking in relation to death rates of one million men and women.  
Nat. Cancer Inst. Monogr., 1966, 19, 122-204.

Hanson, P.  
The Joy of Stress.  
London: Pan, 1987.

Hardveit, F.  
Autopsy findings in cases with a clinically uncertain diagnosis.  
J. Pathol., 1979, 129, 111-119.

Harvald, B. & Hauge, M.  
Hereditary factors elucidated by twin studies. In: J.V. Weel, M.V. Shaw and W.J. Schull (Eds.). Genetics and the epidemiology of chronic diseases. Washington: Publ. Hlth. Serv., 1963.

Heasman, M.A. & Lipworth, L.  
Accuracy of certification of cause of death.  
London: H.M.S.O., 1966.

Heller, W-D.

2023136854

Lung cancer and passive smoking.

Lancet, 1983, 2, 1309.

Herberman, R.

Cancer, AIDS, chronic fatigue and NK cells. UCLA Symposium on Behavioral Neuroimmunology. April 13th, 1988.

Quoted by Solomon, in press.

Hirayama, T.

Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan.

Brit. Med. J., 1981a, 1, 183-185.

Hirayama, T.

Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan.

Brit. Med. J., 1981b, 2, 916-917.

Hirayama, T.

Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan.

Brit. Med. J., 1981c, 2, 1466

Holme, I.

On the separation of intervention effects of diet and anti-smoking advice on the incidence of major coronary events in coronary high risk men. The Oslo Study. J. Oslo City Hosp., 1982, 32, 31-54.

Hopkins, P.N., & Williams, R.R.

A survey of 246 suggested coronary risk factors.

Atherosclerosis, 1981, 40, 1-52.

Hutchison, G.B.

The nature of epidemiologic evidence: smoking and health.

Bull. N.Y. Acad. Med., 1968, 44, 1471-1475.

2023136855

Irwin, M., Daniels, E.T., Bloom, T.L., Smith, H., & Weiner, H.

Life events, depressive symptoms, and immune function.

Amer. J. Psychiat., 1987, 144, 437-441.

Irwin, M., Vale, W., & Britton, K.

Central cortico-tropin-releasing factor suppressor

natural killer cell cytotoxicity.

Brain, Behav. Immunity, 1987, 1, 81-87.

Jarvis, M., West, R., Tunstall-Pedoe, H., & Vesey, C.

An evaluation of the intervention against smoking with

Multiple Risk Factor Intervention Trial.

Prevent. Med., 1984, 13, 501-509.

Jemmott III, J.B., & Locke, S.E.

Psychosocial factors, immunologic mediation, and human

susceptibility to infectious diseases: How much do we know?

Psychol. Bull., 1984, 95, 78-108.

Jemmott III, J.B., & Magloire, K.

Academic stress, social support, and secretory immunoglobin A.

J. Person. & Soc. Psychol., 1988, 55, 803-810.

Johnston, D.W.

Will stress management prevent coronary heart disease?

The Psychol., 1989, 2, 275-278.

Justice, A.

Review of the effects of stress on cancer in laboratory animals:

Importance of time of stress application and type of tumor.

Psychol. Bull., 1985, 98, 108-138.

Kagan, A., Katsuki, S., Sternley, N. & Vanecek, R.

Reliability of death certificate data on vascular lesions  
affecting the central nervous system.

2023136856

Bull. W.H.O., 1967, 37, 477-483.

Kahn, M.A.

The Dorn study of smoking and mortality among U.S. veterans:  
Report on eight and one-half years of observation.

Nat. Cancer Inst. Monogr., 1966, 19, 1-125.

Kannel, W.B.

Update on the role of cigarette smoking in coronary heart  
disease.

Amer. Heart J., 1981, 101, 319-327.

Kannel, W.B., D'Agostino, R.B., & Belanger, A.J.

Fibrinogen, cigarette smoking and risk of cardiovascular  
disease: insights from the Framingham Study.

Amer. Heart J., 1987, 113, 1006-1010

Kannel, W.B., & Gordon, T.

The Framingham Study. An epidemiological Investigation of  
Cardiovascular Disease.

Washington, D.C.: N.I.H., 1970.

Kannel, W.B., Neaton, J.D., Wentworth, D., et al.

Overall and coronary heart disease mortality rates in relation  
to major risk factors in 325,348 men screened for the MRFIT.

Amer. Heart J., 1986, 112, 825-836.

Kaplan, J.R., Manuck, S.B., Clarkson, T.B., Lusso, F.M., Taub, D.M.,  
& Miller, E.W.

Social stress and atherosclerosis in normocholesterolemic  
monkeys. Sci., 1978, 220, 733-735.

Katz, L.

Hearings on Cigarette Labelling and Advertising, Part 2.

Washington, D.C.: Committee on Interstate and Foreign Commerce,  
House of Representatives, 1969.

2023136857

Kennedy, S., Kiecolt-Glaser, J., & Glaser, R.

Immunological consequences of acute and chronic stressors:

Mediating role of interpersonal relationships.

Brit. J. Med. Psychol., 1988, 61, 77-85.

Kern, W.H., Jones, J.C. & Chapman, V.D.

Pathology of bronchogenic carcinoma in long term survivors.

Cancer, 21, 772-780.

Keys, A.

Diet and coronary heart disease throughout the world.

Cardiol. Pract., 1962, 13, 225-244.

Kiecolt-Glaser, J., Garner, W., Speicher, C., Penn, G., Halliday, J.,

and Glaser, R.

Psychosocial modifiers of immunocompetence in medical students.

Psychosom. Med., 1984, 46, 7-14.

Kiecolt-Glaser, J., Glaser, R., Williger, D., Stunt, J., Merrick, G.,

Sheppard, S., Rickers, D., Ramisker, C., Briner, W., Bonnell, G.,

& Damenberg, R.

Psychosocial enhancement of immunocompetence in a geriatric

population. Hlth. Psychol., 1985, 25-41.

Kiecolt-Glaser, J., Rickers, D., George, J., Merrick, G., Speicher,

C.E., Garner, W., & Glaser, R.

Unitary cortisol levels, cellular incompetency, and loneliness in

psychiatric inpatients. Psychosom. Med., 1984, 46, 155-23.

Kleinbaum, D.G., Kupper, L.L., & Morganstern, H.

Epidemiological Research: Principles and Quantitative Methods.

Belmont, C.A.: Lifetime Learning Publications, 1982, 403-418.

Knorring, L. von, & Oreland, L.

Personality traits and platelet monoamine oxidase in tobacco

2023136858

smokers. Psychol. Med., 1985, 15, 327-334.

Korneva, E.A., Klimenko, V.M., & Shkhinek, E.K.  
Neurohormonal Maintenance of Immune Homeostasis.  
Chicago: The University of Chicago Press, 1985.

Kooperman, J.S.  
Interaction between discrete causes.  
Amer. J. Epidem., 1981, 113, 716-724.

Kune, G.A., Kune, S., Watson, L.F., & Bahnson, C.B.  
Personality as a risk factor in large bowel cancer.  
Psychol. Med., in press.

Landenslager, M.L., Ryan, S.M., Drugan, R.C., Hyson, R.C., & Maier, S.F.  
Coping and immunosuppression: Inseparable but not escapable stress suppresses lymphocyte proliferation.  
Sci., 1983, 221, 568-570.

Leaventon, P.E., et al.  
Representativeness of the Framingham Risk Model for coronary heart disease mortality: a comparison with a national cohort study. J. Chron. Dis., 1987, 40, 775-784.

Lee, P.N.  
Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan.  
Brit. Med. J., 1981, 2, 1465-1466.

Le Fanu, J.  
Eat your heart out: The fallacy of the "Healthy Diet".  
London: Macmillan, 1987.

Levy, S.  
Behaviour and Cancer.

2023136859

London: Jossey-Bass, 1985.

Levy, S., Herberman, R., Lippman, M., & d'Angelo, T.  
Correlation of stress factors with sustained depression of  
natural killer cell activity and predicted prognosis in patients  
with breast cancer.  
J. Clin. Ocol., 1987, 5, 348-353.

Leren, P., Askevold, O., Froiti, A., Grymyr, D., Helgeland, A.,  
Hjermann, I., Holme, I., Lund-Larsen, P., Norum, K.  
The Oslo study. Cardiovascular disease in  
middle-aged and young Oslo men.  
Acta Med. Scand., 1975, Suppl. 5888, 1-38.

Levy, S., Herberman, R.B., Maluish, A.M., Schliem, B., & Lippman, M.  
Prospective risk assessment in primary breast cancer:  
behavioural and immunological parameters.  
Health Psychol., 1985, 4, 99-113.

Linn, B., Linn, M., & Klimas, N.  
Effects of psychophysical stress on surgical outcome.  
Psychosom. Med., 1988, 50, 230-244.

Linn, B.S., Linn, M.W., & Jensen, J.  
Anxiety and immune repressiveness.  
Psychol. Rep., 1981, 49, 969-970.

Linn, M.W., Linn, B.S., & Jensen, J.  
Stressful events, dysphoric mood, and immune responsiveness.  
Psychol. Rep., 1984, 54, 219-222.

Lovibond, S.H., Birrell, P.C., & Langeluddecke, P.  
Changing coronary heart disease risk-factor states:  
The effects of three behavioral programs.  
J. Behav. Med., 1986, 9, 915-937.

Lyon, J.L., Gardner, J.W., & West, D.W.

2023136860

Cancer incidence in Mormons and non-Mormons  
in Utah during 1967-75.

J. Nat. Cancer Inst., 1980, 65, 1063-1071.

MacMahon, S.

Alcohol consumption and hypertension.

Hypertension, 1987, 9, 111-121.

Mainland, D., & Herrera, L.

The risk of biased selection in forward going surveys  
with non-professional interviewers.

J. Chron. Dis., 1956, 4, 240-244.

Mann, G.V.

Diet-heart: End of an era.

New England J. Med., 1977, Sept. 22, 644-649.

Mantel, N.

Non-smoking wives of heavy smokers have a  
higher risk of lung cancer: a study from Japan.

Brit. Med. J., 1981, 2, 914-915.

Mantel, N., & Haenszel, W.

Statistical aspects of the analysis of data from  
retrospective studies of disease.

J. Nat. Cancer Inst., 1959, 22, 789-798.

McCarthy, E.G. & Widmer, G.W.

Effects of screening by consultants on recommended  
elective surgical procedures.

The New England J. Med., 1974, 291, 1331-1335.

McClelland, D.C., Floor, E., Davidson, R.J., & Saron, C.

Stressed power motivation, sympathetic activation, immune

2023136861

function and illness. J. Hum. Stress, 1980, 6, 11-19.

McClelland, D.C., Ross, G., & Patel, V.

The effects of an academic examination on salivary norepinephrine and immunoglobin levels.

J. Hum. Stress, 1985, 11, 52-59.

McCormick, J., & Skrabaneck, P.

Coronary heart disease is not preventable by population interventions.

Lancet, 1988, Oct. 8, 839-841.

McLennan, R., da Costa, J., Day, N.E., Law, C.H., Ng, Y.K., & Shanmugaratnam, K.

Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates.

Internat. J. Cancer, 1977, 20, 854-860.

McMichael, A.J.

Increases in laryngeal cancer in Britain and Australia in relation to alcohol and tobacco consumption trends.

The Lancet, 10th June, 1978, 1244-1247.

McMichael, J.

Fats and atheroma: An inquest.

Brit. Med. J., 1979, 20 Jan., 173-175.

Miettinen, T.A., Huttunen, J., Naukkarinen, V., Strandberg, T., Mattila, S., Kumlin, T., & Saura, S.

Multifactorial primary prevention of cardiovascular diseases in middle-aged men: risk-factor changes, incidence and mortality. J. A. Med. Ass., 1985, 254, 2097-2101.

Miller, N.

Behavioral Medicine: Symbiosis between laboratory and clinic.

2023136862

Amer. Rev. Psychol., 1983, 34, 1-31.

Miller, N.

Effects of emotional stress in the immune system.

Pavlov. J. Biol. Sci., 1985, 20, 47-52.

Miller, S.M.

Predictability and human stress: Toward a clarification of evidence and theory. Advances in exp. soc. Psychol., 1981, 14, 203-256.

Monjem, A.A.

Effects of acute and chronic stress upon lymphocyte blastogenesis in mice and humans. In: E.L. Cooper (Ed.), Stress, Immunity, and Aging. Pp. 81-108.

New York: Marcel Dekker, 1984.

Multiple Risk Factor Intervention Trial Research Group.

Multiple risk factor intervention trial.

J. Amer. Med. Asscn., 1982, 248, 1465-1477.

Murphy, J.A., Morrison, R.P., Sobol, A.M., Leighton, A.H.

Affiliated disorders and mortality.

Archives of General Psychiatry, 1987, 44, 473-480.

National Health and Medical Research Council.

Effects of Passive Smoking on Health.

Canberra: Australian Government Publicity Service, 1987.

Nelson, D.V., Friedman, L.C., Baer, P.E., Lane, M., & Smith, F.E.

Attitudes to cancer: Psychometric properties of fighting spirit and denial. J. Behav. Med., 1989, 12, 341-355.

Nemeroff, C., Widerloo, E., Bissette, G., Walleus, H.,

Karlsson, I., Eklund, R., Kilts, C., Larsen, P., & Vale, W.

Elevated concentrations of cortico-tropin-releasing factor-like

2023136863

activity in depressed patients.

Sci., 1984, 226, 1342-1344.

O'Connor, K., & Stravynski, A.

Evaluation of a smoking typology by use of a specific behavioural substitution method of self-control.

Behav. Res. & Ther., 1982, 20, 279-288.

Oeser, H.

Krebs: Schicksal oder Verschuldung?

Stuttgart: Thieme, 1979.

Oliver, M.F.,

Does control of risk factors prevent coronary heart disease?

Brit. Med. J., 1982, 285, 1065-1066.

Oliver, M.F.,

Reducing cholesterol does not reduce mortality.

J. Amer. College Cardiol., 1988, 12, 814-817.

Otis, M.A.,

A study of suggestibility in children.

Archives of Psychol., 1924, 11, (70).

Paganini-Hill, A., Char, A., Ross, R.K., & Henderson, B.E.

Aspirin use and chronic disease: a cohort study of the elderly.

Brit. Med. J., 1989, 299, 1247-1250.

Passey, R.D.

Some problems of lung cancer.

Lancet, 1961, 11, 107-112.

Patel, C., Marmot, M.G.B., Terry, D.J., Carruthers, M.,

Hunt, B., & Patel, M.

Trial of relaxation in reducing coronary risk:  
four year follow-up.

2023136864

Brit. Med. J., 1985, 290, 1103-1186.

Pearl, R.

The rate of living.

New York: A.A. Knopf, 1925.

Pennebaker, J.W., Kiecolt-Glaser, J., & Glaser, R.

Disclosure of traumas and immune function:

Health implications for psychotherapy.

J. Consult. & Clin. Psychol., 1988, 56, 235-245.

Perkins, D.A.

Interaction among coronary heart disease risk factors.

Annals of Behav. Med., 1989, 11, 3-11.

Perkins, K.A.

The synergistic effect of smoking and serum cholesterol on coronary heart disease.

Hlth Psychol., 1985, 4, 337-360.

Perkins, K.A.,

Use of terms to describe results: "Additive", "synergistic".

Psychophysiology, 1987, 24, 719-720.

Pettingale, K.W., Philalithis, A., Tee, D., & Greer, H.S.

The biological correlates of psychological responses to breast cancer. J. Psychosom. Res., 1981, 25, 453-458.

Pettingale, K.W., Morris, T., Greer, S., & Haybittle, J.L.

Mental attitudes to cancer: An additional prognostic factor.

Lancet, 1985, 2, 750.

Physicians' Health Study Research Group.

Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.

New England J. Med., 1988, 318, 262-264.

2023136865

Pike, M.C., & Doll, R.

Age at onset of lung cancer: Significance in relation  
to effect of smoking.

Lancet, 1965, March, 665-668.

Ploeg, H. van der, Kleijn, W.C., Mook, J., Hunge, M. van,

Pieters, A., & Leer, J-W.

Rationality and antiemotionality as a  
risk factor for cancer: Concept differentiation.

J. Psychosom. Res., 1989, 33, 217-225.

Plotnikoff, N., Faith, R., Murgo, A., & Good, R.A. (Eds.).

Enkeptalines and Endorphins: Stress and the Immune System.

New York: Plenum Press, 1986.

Pohler, G.

Krebs und Seelischer Konflikt.

Frankfurt: Nexus, 1989.

Pomerleau, V.E., & Pomerleau, C.S.

Neuroregulators and the reinforcement of smoking:  
Towards a biobehavioral explanation.

Neurosci. and Biobehav. Rev., 1984, 8, 503-513.

Price, V.A.

Type A Behavior Pattern.

New York: Academic Press, 1982.

Quander-Blaznik, J.

Personality as a predictor of lung cancer: a replication.

Person. individ. Diff., in press.

Reid, D.D., & Rose, G.A.

Assessing the comparability of mortality statistics.

Brit. med. J., 1964, 2, 1437-1439.

Rodin, J..

2023136866

Managing the stress of aging: The role of control and coping.

In: S. Levine, & H. Urrin (Eds.), Coping and Health, Pp. 171-202.

New York: Plenum Press, 1984.

Rodin, J.

Health, control and aging. In. M. Baltes & P.B. Baltes (Eds.),

Aging and the Psychology of Control.

Hillsdale, N.J.: Lawrence Erlbaum, 1986.

Roos, B., Vernet, J., & Abelin, T. (Eds.).

Rauchen und Sterblichkeit in der Schweiz.

Bern: Bundesamt fur Gesundheitswesen, 1989.

Rose, G., & Hamilton, P.J.S.

A randomized controlled trial of the effect on  
middle-aged men of advice to stop smoking.

J. Epidem. & Comm. Hlth., 1978, 32, 275-281.

Rose, G., Hamilton, P., Colvell, L., & Shipley, M.

A randomized controlled trial of anti-smoking advice:  
10-year results.

J. Epidem. & Comm. Hlth., 1982, 36, 102-108.

Rosenblatt, M.B.

Lung cancer and smoking - The evidence reassessed.

New Sci., 1974, May, 332.

Rosenblatt, M.B., Teng, P.K., Kerpe, S., & Beck, I.

Prevalence of lung cancer: Disparity between clinical and autopsy  
certification. Med. Counterpoint, 1971b, 33, 53-59.

Rothman, K.J.

Synergy and antagonism in cause-effect relationships.

Amer. J. Epidem., 1974, 99, 385-388.

Rothman, K.J., & Keller, A.Z.

2023136867

The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx.

J. Chron. Dis., 1972, 23, 711-716.

Rothman K.J., Cann, C.I., Flanders, D., & Fried, M.P.

Epidemiology of laryngeal cancer.

Epidem. Rev., 1980, 2, 195-209.

Rou, B., Rose, J., Sunderland, T., Moritisa, J., & Murphy, D.

Antisomatostatin G in major depressive disorder. A preliminary study with implications for autoimmune mechanisms of depression. Arch. Gen. Psychiat., 1988, 45, 924-928.

Royal College of Physicians.

Smoking and Health Now.

London: Pitman, 1971.

Saracci, R.

The interactions of tobacco smoking and other agents in cancer etiology. Epidem. Rev., 1987, 9, 135-193.

Scheier, M.F., Matthews, K.A., Owens, J.F., Magorem, G.J.,

Lefebvre, R.C., Abbot, R.A. & Carver, C.S.

Dispositional optimism and recovery from coronary artery bypass surgery: The beneficial effects of physical and psychosocial well-being.

J. Person. Soc. Psychol., 1989, 57, 1024-1040.

Schleifer, S., Keller, S., Meyerson, A., Roskin, M.,

Davis, K., & Stein, M.

Lymphocyte function in major depressive disorders.

Arch. Gen. Psychiat., 1984, 41, 484-486.

Schatzkin, A., Hoover, R.N., Taylor, P.R., Ziegler, R.C.,

Carter, C.L., Albans, D., Larson, D.B., & Licitra, L.M.

Site-specific analysis of total serum cholesterol and

2023136868

incident cancer in the National Health and Nutrition Examination Survey. I. Epidemiologic follow-up study.  
Cancer Res., 1988, 48, 452-458.

Sehrt, E.

Beitrage zur Kenntnis des Primaren Lungencarcinoma.  
Leipzig: George, 1904.

Seltzer, C.C.

An evaluation of the effect of smoking on coronary heart disease.

J. Amer. Med. Asscn., 1968, 203, 193-200.

Seltzer, C.C.

Framingham study data and "established wisdom" about cigarette smoking and coronary heart disease.

J. Clin. Epidem., 1989, 42, 743-750.

Shavit, Y., Lewis, J., Terman, G., Gale, R., & Leibeskind, J.

Opioid peptides mediate the suppressive effects of stress on natural killer cell cytotoxicity.

Sci., 1989, 223, 188-190.

Sunarak, S., de Jong, U.W., Breslow, N., Dahl, C.J.,

Ruckphaopunt, K., Scheelings, P., & MacLennan, R.

Cancer of the oral cavity, pharynx/larynx and lung in North Thailand: Case control study and analysis of cigar smoke.

Brit. J. Cancer, 1977, 36, 130-140.

Smithers, D.W.

Facts and fancies about cancer of the lung.

Brit. Med. J., 1953, 1, 1235-1239.

Solomon, G.

The emerging field of psychoneuroimmunology.

2023136869

Advances, 1985, 2, 6-19.

Solomon, G.

Psychoneuroimmunology: Interaction between central nervous system and immune system.

J. Neurosis. Res., 1987, 18, 1-9.

Solomon, G.

Psychoneuroimmunology revisited, 1988. Exponential but uneven growth. (In press).

Solomon, G., Levine, S., & Kraft, J.

Early experience and immunity.

Nature, 1968, 220, 821-822.

Solomon, G., & Moos, R.

Emotions, immunity and disease: A speculative theoretical intergration. Arch. Gen. Psychiat., 1964, 11, 657-674.

Solvason, H., Ghanta, V., & Hiramoto, R.

Conditional augmentation of natural killer cell activity.

Independence on interferon-beta.

J. Immunol., 1988, 140, 661-665.

Spiegel, D., Bloom, J.R., Kraemer, H.C., & Gottleib, E.

Effect of psychosocial treatment on survival of patients with metastatic breast cancer.

Lancet, 1989, Oct. 14, 888-891.

Spielberger, C.D.

Psychological determinants of smoking behavior.

In: R.D. Tollison (Ed.), Smoking and Society. Pp. 89-134.

Toronto: Lexington Books, 1986.

Stebbins, J.H.

Chronic respiratory disease among non-smokers in

2023136870

Hagerstown, Maryland. Part II: Problems in the estimation  
of pulmonary function values in epidemiological surveys.

Environment. Res. 1971, 4, 163-192.

Stell, P.M.,

Smoking and laryngeal cancer.

The Lancet, March 18, 1972, 617-618.

Steptoe, A.

Psychological Factors in Cardiovascular Disorders.

New York: Academic Press, 1981.

Steptoe, A.

Coping and psychophysiological reaction.

In: S. Miller (Ed.). Special Issue of Advances in Behaviour  
Research and Therapy, Pp. 259-270.

Oxford: Pergamon Press, 1989, 11, No. 4.

Sterling, T.D.

The statistician vis-a-vis issues of public health.

The Amer. Statistn., 1973, 27, 212-217.

Sterling, T.D.

New evidence concerning smoking and health.

Med. J. Austral., 1977, Oct. 15, 538-542.

Stone, A.A., Cox, D.S., Valdimarsdottir, H.,

Jandorf, L., & Neale, J.G.

Evidence that secretory IgA antibody is associated  
with daily mood. J. Person. Soc. Psychol., 1987, 52, 988-993.

Taylor, S.E.

Health psychology. Amer. Psychol., 1990, 45, 40-50.

Temoshok, L.

Personality, coping style, emotion and cancer:  
towards an integrative model.

2023136871

Cancer Surveys, 1987, 6, 545-567.

Teshina, H.

Recent biopsychosociological approaches to cancer

study in Japan. In: S.B. Day (Ed.),

Cancer, Stress, and Death. Pp. 79-87.

New York: Plenum, 1986.

Thurlbeck, W.M., Anderson, A.E., Jarvis, M., Mitchell, R.S.,

Pratt, P., Restrepo, G., Ryan, S.F. & Vincent, T.

A co-operative study of certain measurements of emphysema.

Thorax, 1968, 23, 217-228.

Tomkins, S.S.

A modified model of smoking behavior. In: E.F. Borgatta,

& R. Evans (Eds.), Smoking, Health and Behavior.

Chicago: Aldine, 1968.

Trichopolous, D.

Passive smoking and lung cancer.

Lancet, 1989, 2, 684.

Trichopolous, D., Kalondidi, A., & Sparrow, L.

Lung cancer and passive smoking: conclusion of Greek study.

Lancet, 1983, 2, 677-678.

Trichopolous, D., Kalondidi, A., Sparrow, L., & Macmahon, B.

Lung cancer and passive smoking.

Internat. J. Cancer, 1981, 27, 1-4.

U.S. Department of Health and Human Services.

Nicotine addiction: A report of the Surgeon-General.

Rockville, Md., Off. Smok. Hlth., 1988.

U.S. Surgeon-General.

Health consequences of smoking.

2023136872

Washington: U.S. Dept. Hlth. Educ. & Welf., 1979.

U.S. Surgeon-General.

The health consequences of smoking - cancer.

Rockville, Md.: U.S. Dept. Hlth. & Hum. Servs., 1982.

U.S. Surgeon-General.

The health consequences of involuntary smoking.

Rockville, Md.: U.S. Dept. Hlth. & Hum. Servs., 1986.

U.S. Surgeon-General

Reducing the health consequences of smoking: 25 years of progress.

Rockville, Md.: U.S. Dept. Hlth. & Human Servs., 1989.

Vecchia, C. la, Levi, F., & Gutzwiller, F.

Fumée et santé: une épidémie évitable.

Med. et Hyg., 1987, 45, 3435-3462.

Wakefield, J.

Results and methodological quality of smoking and health studies.

Person. Individ. Diff., 1988, 9, 465-477.

Waldron, H.A. & Vickerstaff, L.

Intimations of quality.

Oxford: Nuff. Prov. Hosp. Trust, 1977.

Walker, A.M.

Proportion of disease attributable to the combined effect of two factors. Internat. J. Epidem., 1981, 10, 81-85.

Warburton, D.M.

Addiction, dependence and habitual substance use.

Bull. Brit. Psychol. Soc., 1985, 38, 285-288.

Warburton, D.M.

Is nicotine use an addiction?

The Psychol., 1989, 4, 166-170.

2023136873

Warburton, D.M., Revell, A., & Walter, A.C.

Nicotine as a resource. In: M.J. Rand & K. Tharan, (Eds.),

The Pharmacology of Smoking. Pp. 359-373..

Oxford: IRL Press, 1988.

Wells, H.G.

Relation of clinical to necropsy diagnosis in cancer  
and value of existing cancer statistics.

J. Amer. Med. Assn., 1923, 80, 737-740.

Wilhelmsen, L., Wedel, H., & Tibblin, G.

Multivariate analysis of risk factors for coronary heart  
disease. Circulation, 1973, 48, 950-958.

Wilhelmsen, L., Berglund, G., Elmfeld, E., Tibblin, G., Wedel, H.,

Pennert, K., Vedin, A., Wilhelmsen, C., & Werker, L.

The multifactor primary prevention trial in Goteborg.

Euro. Heart J., 1986, 7, 279-288.

Willis, R.A.

Pathology of Tumours, (4th ed.).

London: Butterworth.

Wilson, E.B. & Burke, M.H.

Some statistical observations as a co-operative study  
of human pulmonary pathology.

Proc. Nat. Acad. Sci., 1957, 43, 1073-1078.

Wirsching, M., Stierlin, H., Weber, G., Wirsching, B., & Hoffman, F.

Brustbrebs im Kontext: Ergebnisse einer Vorhersagestudie  
und Konsequenzen fur die Therapie.

Zchr. psychosom. Medizin, 1981, 27, 239-252.

Workman, E.A., & La Via, M.F.

T lymphocyte polyclonal proliferation and stress response style.

2023136874

Psychol. Rep., 1987, 60, 1121-1122.

World Health Organization (Eds.).

A 5-year Action Plan: Smoke-free Europe.

Copenhagen: WHO Regional Office for Europe, 1988.

Wynder, E.L.

Workshop on guidelines to the epidemiology of weak association.

Prev. Med., 1987, 16, 139-141.

Yerushalmy, J.

On inferring causality from observed associations.

In: F.J. Ingelpinger, A.S. Relman & M. Finland (Eds.).

Controversy in Internal Medicine.

London: W.B. Saunders, 1966.

Yesner, R.

Observer variability and reliability in lung cancer diagnosis.

Cancer Chemoth. Rep. 1973, 4, 55-57.

Yesner, R., Selfman, N.A. & Feinstein, A.R.

A reappraisal of histopathology in lung cancer and

correlation of all types with antecedent cigarette smoking.

Amer. Rev. Respirat. Dis., 1973, 107, 790-797.

Zonderman, A.B., Costa, P.T., & McCrae, R.R.

Depression as a risk factor for cancer morbidity and mortality

in a nationally representative sample.

J. Amer. Med. Ass., 1989, 262, 1191-1195.

2023136875

## C A P T I O N S

Table 1. Comparison of CHD morbidity ratios and incidence rates of never-smokers and ex-smokers at various years of follow-up.  
(After Seltzer, 1989.)

- " 2. CHD risk ratios (cigarette smokers/non-smokers) calculated from the Framingham Heart Study incidence data.  
(After Seltzer, 1989.)
- " 3. Comparison of U.S. Surgeon-General's coronary heart disease findings and those of the Framingham Study data with respect to cigarette smoking.  
(After Seltzer, 1989.)
- " 4. Causes of death for different types of probands - Yugoslav sample.  
(Grossarth-Maticek & Eysenck, 1980.)
- " 5. Causes of death for different types of probands - Heidelberg normal sample.  
(Grossarth-Maticek & Eysenck, 1988.)
- " 6. Causes of death for different types of probands - Heidelberg stressed sample.  
(Grossarth-Maticek & Eysenck, 1988.)
- " 7. Interaction between smoking, personality and death from lung cancer. (Grossarth-Maticek & Eysenck, 1988.)
- " 8. Relative importance of personality and organic risk factors for death.  
(Grossarth-Maticek, Eysenck & Vetter, 1988.)
- " 9. Synergistic effects of H (heredity), B (chronic bronchitis), C (cigarette smoking) and S (stress/personality), BT (behaviour therapy.)  
(Grossarth-Maticek & Eysenck, in press.)
- " 10. Effects of behaviour therapy on cancer and coronary heart disease.  
(Grossarth-Maticek & Eysenck, 1989.)
- " 11. Effects of group behaviour therapy on cancer and coronary heart disease.  
(Grossarth-Maticek & Eysenck, 1989.)
- " 12. Effects of bibliotherapy and short behaviour therapy on cancer and coronary heart disease.  
(Grossarth-Maticek & Eysenck, 1989.)

2023136876

TABLE 1.

| Follow-up.                 | Morbidity ratios*<br>or incidence rate |      | Proportionate<br>difference |
|----------------------------|--|------|-----------------------------|
| 9.1 yr                     | Never smokers                          | 7.7  | +67%                        |
|                            | Past "                                 | 4.6  |                             |
| 12-yr<br>("heart attacks") | Never smokers                          | 8.2  | +39%                        |
|                            | Ex-smokers                             | 5.9  |                             |
| 16-yr                      | Never smokers                          | 9.1  | +49%                        |
|                            | Ex-smokers                             | 6.1  |                             |
| 18-yr<br>("heart attacks") | Never smokers                          | 17.7 | +36%                        |
|                            | Ex-smokers                             | 13.0 |                             |
| 22-yr                      | Never smokers                          | 29.8 | +23%                        |
|                            | Ex-smokers                             | 24.2 |                             |

\*Ratio of observed to expected rate (100 times those observed divided by those expected).

~CHD incidence rates per 100 men.

2023136877

TABLE 2

| Follow-up   | Incidence                              | Ages  | Nonsmoker classification for comparison with smokers* |     | Risk Ratios |       |
|---|--|---|---|-----|-------------|-------|
|   |  |   |   |     | Men         | Women |
| 9.1 yr After Exam 1   | 40-59                                  | Never smokers<br>Nonsmokers (never,<br>past, <half day) | 1.5~  | -   |             |       |
| 12-yr After Exam 1  | 30-59                                  | Non-cigarette   | 1.8~  | -   |             |       |
| 14-yr After Exam 1  | 35-64                                  | None  | 1.4   | 0.9 |             |       |
| 16-yr After Exam 1  | 35-64                                  | None  | 1.3   | 0.9 |             |       |
|   | Average annual 35-74<br>incidence rate | None  | 1.3   | 0.8 |             |       |
| 18-yr Average annual 45-74<br>incidence rate                | 45-74                                  | None  | 1.3   | 1.0 |             |       |
| 20-yr Average annual 45-74<br>"smoothed"<br>rate            | 45-74                                  | None  | 1.4   | -   |             |       |
| 22-yr After Exam 1  | 30-59                                  | Non-cigarette   | 1.3   | 0.8 |             |       |
| 24-yr After Exam 1  | 30-59                                  | Non-cigarette   | 1.3   | 0.9 |             |       |
| 26-yr After Exam 1  | 35-84                                  | Non-cigarette   | 1.3@  | -   |             |       |
| 30-yr Average annual 35-64<br>incidence rate 35-74<br>35-84 | 35-64<br>35-74<br>35-84                | None  | 1.6   | 1.1 |             |       |
|   |  |   | 1.3   | 1.0 |             |       |
|   |  |   | 1.0   | 1.0 |             |       |

\* Age-adjusted by assigning equal weights to rates in each age-group, in accordance with Framingham method listed in Table 1.

^ Framingham categories of "none" and "non-cigarette" include ex-smokers, and pipe and cigar smokers in addition to "never smokers".

~ "Standardized incidence ratios" with CHD limited to non-fatal and fatal MI, and sudden CHD death.

|| Framingham "morbidity ratios".

@ Framingham "coronary morbidity".

2023136878

TABLE 3

| Criteria                          | U.S.<br>Surgeon-General's<br>findings                      | Framingham data<br>findings   |
|-----------------------------------|--|---|
| Men-Univariate association        | Strong   | Weak  |
| Men-Multivariate "                | Strong   | Non-significant;<br>absent  |
| Women-Univariate "                | Present, but less<br>than in men                           | Absent  |
| Women-Multivariate "              | Present  | Absent  |
| Duration of<br>cigarette smoking  |  | Absent  |
|                                   | Increase of CHD<br>with increase of<br>duration of smoking |   |
| Cessation of<br>cigarette smoking | Gradual reduction<br>of CHD to level<br>of non-smokers     | Immediate<br>reduction of CHD<br>to level below that<br>of never smokers. |

2023136879

Table 4.

| Yugoslavia                           | Living      | Cancer      | Coronary,<br>heart<br>disease | Other<br>causes of<br>deaths | Total N |
|--------------------------------------|-------------|-------------|-------------------------------|------------------------------|---------|
| Type 1                               | 72 = 23.8%  | 140 = 46.2% | 23 = 8.3%                     | 66 = 23.8%                   | 303     |
| Type 2                               | 96 = 28.3%  | 19 = 5.6%   | 99 = 29.2%                    | 125 = 36.9%                  | 339     |
| Type 3                               | 123 = 36.7% | 4 = 1.3%    | 20 = 9.2%                     | 70 = 32.3%                   | 217     |
| Type 4                               | 437 = 90.7% | 3 = 0.6%    | 8 = 1.7%                      | 34 = 7.1%                    | 482     |
| Impossible<br>to allocate<br>to type | 6           | 0           | 4                             | 2                            | 12      |
| Total                                | 738 = 33.2% | 166 = 12.3% | 156 = 11.5%                   | 297 = 27.0%                  | 1353    |

2023136880

Table 5.

| Heidelberg<br>normal                 | Living      | Cancer     | Coronary<br>heart<br>disease | Other<br>causes of<br>deaths | Total<br>N |
|--------------------------------------|-------------|------------|------------------------------|------------------------------|------------|
| Type 1                               | 78 = 70.6%  | 19 = 17.4% | 2 = 1.8%                     | 10 = 9.2%                    | 109        |
| Type 2                               | 109 = 64.1% | 10 = 5.9%  | 23 = 13.5%                   | 28 = 16.5%                   | 170        |
| Type 3                               | 185 = 98.4% | 0          | 1 = 0.5%                     | 2 = 1.1%                     | 188        |
| Type 4                               | 387 = 99.0% | 0          | 11 = 0.3%                    | 3 = 0.8%                     | 391        |
| Impossible<br>to allocate<br>to type | 14          | 0          | 0                            | 0                            | 14         |
| Total                                | 773 = 89.6% | 29 = 3.3%  | 27 = 3.1%                    | 43 = 4.9%                    | 872        |

2023136881

2023136882

| Field/box | Group       | Living      | Cancer      | Other       | Total | Census of | Death      | Death    | N   |
|-----------|-------------|-------------|-------------|-------------|-------|-----------|------------|----------|-----|
| Type 1    | 188 = 38.4% | 188 = 38.4% | 34 = 7.0%   | 79 = 16.2%  | 489   | 309       | 68 = 22.0% | 8 = 4.8% | 309 |
| Type 2    | 149 = 41.9% | 149 = 41.9% | 7 = 2.0%    | 4 = 2.4%    | 366   | 278       | 68 = 22.0% | 8 = 4.8% | 165 |
| Type 3    | 153 = 92.7% | 153 = 92.7% | 0           | 0           | 153   | 92        | 2 = 2.7%   | 2 = 2.7% | 93  |
| Type 4    | 73 = 92.3%  | 73 = 92.3%  | 0           | 0           | 73    | 73        | 0          | 0        | 6   |
| Total     | 566 = 54.3% | 199 = 19.1% | 120 = 11.5% | 157 = 15.1% | 1042  | 611       | 0          | 0        | 6   |

Table 6.

Table 7.

|             | Yugoslavia               |                 |       | Heidelberg (stressed)    |                 |       |
|-------------|--------------------------|-----------------|-------|--------------------------|-----------------|-------|
|             |                          |                 | Total |                          |                 | Total |
|             | Lung<br>cancer<br>deaths | Other<br>deaths |       | Lung<br>cancer<br>deaths | Other<br>deaths |       |
| Non-smokers | Type I                   | 1 = 0.8%        | 108   | 119                      | 9 = 3.8%        | 227   |
|             | Others                   | 0               | 530   | 530                      | 3 = 1.0%        | 300   |
| Smokers     | Type I                   | 31 = 16.9%      | 153   | 184                      | 37 = 14.6%      | 216   |
|             | Others                   | 6 = 1.2%        | 482   | 488                      | 0               | 247   |

2023136883

TABLE 8.

| Type                          | Mean    |        |        | b            |              |              | Mort. (per cent) |             |             |
|-------------------------------|---------|--------|--------|--------------|--------------|--------------|------------------|-------------|-------------|
|                               | Y       | H1     | H2     | Y            | H1           | H2           | Y                | H1          | H2          |
| rf: systolic blood pressure   | 1 151.0 | —      | 174.2  | 0.056        | —            | 0.024        | 7.6              | —           | 7.2         |
| dis: infarct/stroke mortality | 2 160.7 | —      | 207.6  | <u>0.084</u> | —            | <u>0.108</u> | <u>27.2</u>      | —           | <u>23.7</u> |
| 3 148.3                       | —       | 186.3  | 0.005  | —            | 0.010        | 7.7          | —                | 2.3         |             |
| 4 144.6                       | —       | 185.8  | 0.003  | —            | 0.021        | 1.8          | —                | 5.0         |             |
| all 150.7                     | —       | 187.7  | 0.035  | —            | 0.041        | 11.1         | —                | 9.1         |             |
| Significance of differences   | 0.0000  | —      | 0.0000 | 0.0004       | —            | 0.0011       | <0.0001          | —           | <0.0001     |
| rf: diastolic blood pressure  | 1 90.0  | —      | 85.8   | 0.026        | —            | 0.019        | 5.1              | —           | 7.2         |
| dis: infarct/stroke mortality | 2 93.7  | —      | 93.5   | <u>0.091</u> | —            | <u>0.071</u> | <u>26.8</u>      | —           | <u>24.5</u> |
| 3 88.6                        | —       | 88.9   | 0.020  | —            | 0.004        | 8.5          | —                | 2.5         |             |
| 4 86.8                        | —       | 89.0   | 0.014  | —            | 0.007        | 2.1          | —                | 5.5         |             |
| all 89.6                      | —       | 88.8   | 0.038  | —            | 0.025        | 10.6         | —                | 9.9         |             |
| Significance of differences   | 0.0000  | —      | 0.0000 | 0.0137       | —            | 0.0494       | <0.0001          | —           | <0.0001     |
| rf: blood cholesterol         | 1 255.6 | 217.5  | 258.3  | 0.011        | 0.004        | 0.017        | 8.3              | 3.2         | 8.5         |
| dis: infarct/stroke mortality | 2 250.4 | 254.4  | 305.1  | <u>0.036</u> | <u>0.034</u> | <u>0.046</u> | <u>29.4</u>      | <u>9.7</u>  | <u>24.7</u> |
| 3 245.8                       | 216.8   | 282.6  | 0.027  | 0.000        | 0.003        | 9.2          | 1.8              | 1.8         |             |
| 4 245.3                       | 217.9   | 280.3  | 0.001  | 0.001        | 0.000        | 1.8          | 0.8              | 3.5         |             |
| all 249.1                     | 224.9   | 277.8  | 0.019  | 0.014        | 0.020        | 12.2         | 3.9              | 9.6         |             |
| Significance of differences   | 0.0330  | 0.0000 | 0.0000 | NS           | NS           | 0.0486       | <0.0001          | 0.0008      | 0.0000      |
| rf: cigarettes per day        | 1 15.7  | 13.0   | 16.9   | 0.000        | 0.003        | 0.000        | 7.7              | 4.1         | 6.9         |
| dis: infarct/stroke mortality | 2 10.4  | 18.8   | 14.4   | <u>0.038</u> | <u>0.050</u> | <u>0.161</u> | <u>29.8</u>      | <u>12.0</u> | <u>27.6</u> |
| 3 11.6                        | 8.9     | 12.2   | 0.021  | 0.016        | 0.007        | 8.3          | 2.3              | 1.7         |             |
| 4 10.8                        | 8.2     | 10.9   | 0.002  | 0.008        | 0.011        | 1.8          | 1.2              | 3.5         |             |
| all 11.9                      | 11.1    | 15.0   | 0.005  | 0.019        | 0.045        | 11.9         | 3.0              | 9.9         |             |
| Significance of differences   | 0.0000  | 0.0000 | 0.0000 | NS           | NS           | 0.0000       | <0.0001          | 0.0002      | 0.0001      |
| rf: cigarettes per day        | 1 15.7  | 13.0   | 16.9   | <u>0.075</u> | <u>0.019</u> | <u>0.044</u> | <u>8.2</u>       | <u>1.6</u>  | <u>8.2</u>  |
| dis: lung cancer mortality    | 2 10.4  | 18.8   | 14.4   | 0.020        | 0.010        | 0.003        | 2.5              | 2.5         | 1.5         |
| 3 11.6                        | 8.9     | 12.2   | 0.003  | 0.015        | 0.007        | 1.3          | 2.4              | 1.7         |             |
| 4 10.8                        | 8.2     | 10.9   | 0.002  | 0.008        | 0.011        | 0.6          | 1.2              | 3.5         |             |
| all 11.9                      | 11.1    | 15.0   | 0.025  | 0.013        | 0.016        | 3.1          | 2.4              | 3.7         |             |
| Significance of differences   | 0.0000  | 0.0000 | 0.0000 | 0.0001       | NS           | 0.0113       | <0.0001          | NS          | 0.0000      |

largest (abs.) value is underlined

For Yugoslavia, the organic variables represent a single measurement taken in 1966 (cholesterol: 1969).

For Heidelberg, the organic variables are the average of up to 7 measurements taken in 1972.

Abbreviations:

rf = risk factor.

dis. = disease.

mean = mean of organic variable within type groups.

b = regression coefficient of the dependent variable on the organic variable within type groups.

mort. = mortality (the dependent variable) within type groups, adjusted for the organic variable.

Y = Yugoslavia H1 = Heidelberg representative H2 = Heidelberg stressed. NS means  $P > 0.05$ .

202313684

Table 9.

| Combination<br>of risks: | N   | Lung<br>cancer | %  | Other causes<br>of death | %  | Average<br>Age |
|--------------------------|-----|----------------|----|--------------------------|----|----------------|
| Only H                   | 50  | 0              | 0  | 5                        | 10 | 51             |
| Only C                   | 100 | 0              | 0  | 12                       | 12 | 52             |
| <u>Only S</u>            | 59  | 0              | 0  | 16                       | 27 | 52             |
| H + C                    | 50  | 1              | 2  | 4                        | 8  | 53             |
| H + B                    | 52  | 0              | 0  | 8                        | 15 | 51             |
| C + B                    | 55  | 0              | 0  | 11                       | 20 | 52             |
| C + S                    | 100 | 2              | 2  | 21                       | 21 | 53             |
| H + S                    | 49  | 0              | 0  | 9                        | 18 | 54             |
| <u>B + S</u>             | 50  | 0              | 0  | 8                        | 16 | 53             |
| C + H + B                | 26  | 2              | 8  | 5                        | 19 | 51             |
| C + H + S                | 50  | 10             | 20 | 14                       | 28 | 51             |
| <u>C + B + S</u>         | 51  | 5              | 10 | 10                       | 20 | 51             |
| H + C + B + S            | 26  | 8              | 31 | 8                        | 31 | 52             |
| (H+C+B+S+BT)             | 26  | 3              | 12 | 4                        | 15 | 52             |

2023136885

Table 10.

| I.      | N   | CANCER Deaths Incidence |           | Other causes of death | Living    |
|---------|-----|-------------------------|-----------|-----------------------|-----------|
| Control | 50  | 16<br>32%               | 21<br>42% | 15<br>30%             | 19<br>38% |
| Therapy | 50  | 0<br>0                  | 13<br>26% | 5<br>10%              | 45<br>90% |
| TOTAL:  | 100 | 16<br>16%               | 34<br>34% | 20<br>20%             | 64<br>64% |

| II.     | N  | CHD Deaths Incidence |             | Other causes of death | Living      |
|---------|----|----------------------|-------------|-----------------------|-------------|
| Control | 46 | 16<br>34.8%          | 20<br>43.5% | 13<br>28.3%           | 17<br>36.9% |
| Therapy | 46 | 3<br>6.5%            | 11<br>23.9% | 6<br>13%              | 37<br>80.4% |
| TOTAL:  | 92 | 19<br>20.6%          | 31<br>33.7% | 19<br>20.7%           | 54<br>58.7% |

2023136886

Table 11.

| N<br>Not<br>contacted       | Therapy<br>245   |                  | Control<br>245   |                  |
|-----------------------------|------------------|------------------|------------------|------------------|
|                             | 6                | 11               | 6                | 11               |
|                             | <u>Mortality</u> | <u>Incidence</u> | <u>Mortality</u> | <u>Incidence</u> |
|                             | 239              | 235              | 234              | 231              |
| Cancer                      | 18<br>7.5%       | 75<br>31.9%      | 111<br>47.4%     | 129<br>55.8%     |
| CHD                         | 10<br>4.2%       | 29<br>12.3%      | 36<br>15.4%      | 45<br>19.5%      |
| Other<br>causes<br>of death | 20<br>8.4%       | -                | 33<br>14.1%      | -                |
| Living                      | 191<br>79.9%     |                  | 56<br>23.9%      |                  |

2023136887

Table 12.

|  | Causes of Death |              |              |              |              |    |              |              |                  |            |
|--|-----------------|--------------|--------------|--------------|--------------|----|--------------|--------------|------------------|------------|
|  | Cancer          |              | CHD          |              | Other        |    | Total        | Liv-ing      | Not invest-gated |            |
|  | D*              | I*           | D*           | I*           | D*           | I* |              |              |                  |            |
| Control<br>N=500   | 106<br>21.5%    | 162<br>33.4% | 145<br>29.4% | 203<br>41.8% | 164<br>33.3% | -  | 415<br>84.2% | 78<br>15.8%  | 7<br>1.4%        | 15<br>3%   |
| Control<br>with use<br>of psycho-<br>analytic<br>text.<br>(Placebo<br>Group.)<br>N=100 | 22<br>22%       | 37<br>37.7%  | 31<br>31%    | 40<br>40.8%  | 28<br>28%    | -  | 81<br>81%    | 19<br>19%    | 0<br>0%          | 2<br>2%    |
| Therapy<br>Group<br>with<br>Behaviour<br>Therapy<br>Text.<br>N=600                     | 27<br>4.5%      | 99<br>16.9%  | 47<br>7.9%   | 132<br>22.5% | 115<br>19.2% | -  | 189<br>31.6% | 409<br>68.4% | 2<br>0.3%        | 14<br>2.3% |

\* D = died; I = incidence


2023136888

Fig. 1. Cumulative experience of intercourse by age of first intercourse for college educated males and females in the USA. (Data from the National Longitudinal Study.)

- " 2. Effect of different types of treatment on giving up smoking. (O'Connor & Stravynski, 1982.)
- " 3. Personality type and cause of death, Yugoslav study. (Grossarth-Maticek & Eysenck, 1988.)
- " 4. Personality type and cause of death, Heidelberg normal sample. (Grossarth-Maticek & Eysenck, 1988.)
- " 5. Personality type and cause of death, Heidelberg stressed sample. (Grossarth-Maticek & Eysenck, 1988.)
- " 6. Synergistic action of 7 risk factors for cancer. (Grossarth-Maticek & Eysenck, in press a.)
- " 7. Sclerosis in cancer-prone and coronary heart disease-prone probands and effects of behaviour therapy. (Grossarth-Maticek & Eysenck, in press b.)


2023136889

FIG. 1.




2023136830

FIG. 2.




2023136891

YUGOSLAV STUDY




202313692

## HEIDELBERG STUDY (normal group)




2023136893

HEIDELBERG STUDY  
(stressed group)


2023136894

Fig. 6.



2023136895

FIG. 7.



2023136896

APPENDIX

SHORT DISEASE-PRONENESS INVENTORY

(For scoring, see instructions at end of inventory)

1) I find it very difficult to stand up for myself. YES NO

2) I have been complaining for years about various unfavourable conditions, but am not able to change them. YES NO

3) I am mainly concerned with my own well-being. YES NO

4) I am usually content and happy with my daily activities. YES NO

5) I can express my feelings only when there are good reasons for them. YES NO

6) I don't believe in social rules, and don't pay much attention to other people's expectations or the obligations I may have towards them. YES NO

7) I cannot live happily and contentedly with nor without a particular person. YES NO

8) I prefer to agree with others, rather than assert my own views. YES NO

9) Certain people are the most important causes

2023136897

of my personal misfortunes. YES NO

10) I alternate to a great degree between the positive and negative evaluation of people and conditions. YES NO

11) When I cannot achieve closeness with someone who is emotionally important to me, I have no difficulties in letting them go. YES NO

12) I have difficulties in showing my emotions because for every positive emotion there is a negative one. YES NO

13) My behaviour towards other people alters from being very friendly and good-natured to being very hostile and aggressive. YES NO

14) I cannot live happily and contentedly in the presence or the absence of certain states or conditions; e.g. I need my work, but am unhappy doing it. YES NO

15) I tend to act more to fulfill the expectations of people close to me, rather than look after my own needs. YES NO

16) Certain conditions or situations are the most important causes of my personal misfortunes. YES NO

17) With people I love, I keep changing from keeping them at a great distance to stifling dependence, and from stifling dependence to

Source: <https://www.industrydocuments.ucsf.edu/docs/nqv10000>

|     |  | YES | NO |
|-----|--|-----|----|
| 18) | I can usually arrange things so that people who are emotionally important to me are as close to or as distant from me as I wish. | YES | NO |
| 19) | Reason, rather than emotion, guides my behaviour.  | YES | NO |
| 20) | I often expect others to fulfill agreements very strictly, but do not believe in doing so myself.                                | YES | NO |
| 21) | I often have thoughts which terrify me and make me unhappy.  | YES | NO |
| 22) | I tend to give in and abandon my own aims in order to achieve harmony with other people.   | YES | NO |
| 23) | I feel helpless against people or conditions which cause great unhappiness for me, because I cannot change them.                 | YES | NO |
| 24) | When I am in a situation which I experience as threatening, I immediately try to get other people to help and support me.        | YES | NO |
| 25) | When I fail to achieve my objectives, I can easily change tack.  | YES | NO |
| 26) | When people make emotional demands on me, I usually react only rationally, never emotionally.                                    | YES | NO |
| 27) | I usually act in a spontaneous manner, following my immediate feelings without   | YES | NO |

2023136899

considering the actual consequences.

YES NO

28) Relations with certain people are always pretty unsatisfactory, but there is nothing I can do about it. YES NO

29) I am unable to express my feelings and needs openly to other people. YES NO

30) I always seem to be confronted with the undesirable aspects of people and conditions. YES NO

31) When someone who is emotionally important to me hurts me ever so slightly, I immediately dissociate myself from that person. YES NO

32) I can manage to live fairly contentedly with or without someone who is emotionally important to me. YES NO

33) I am quite unable to allow myself to be guided by emotional considerations. YES NO

34) I often feel like attacking other people and crushing them. YES NO

35) Certain situations and states (e.g. at my place of work) tend to make me unhappy, but there is nothing I can do to alter things. YES NO

36) I tend to accept conditions which work against my personal interests without being able to protest. YES NO

37) Certain people keep interfering with my

2023136900

personal development. YES NO

38) I expect others to live up to the highest moral standards, but do not feel that these are binding on myself. YES NO

39) I can usually change my behaviour to suit conditions. YES NO

40) My actions are never influenced by emotions to the degree that they might appear irrational. YES NO

41) When my partner demonstrates love towards me, I sometimes become particularly aggressive. YES NO

42) Certain bodily conditions (e.g. being overweight) make me unhappy, but I feel unable to do anything about it. YES NO

43) I often feel inhibited when it comes to openly showing negative feelings such as hatred, aggression, or anger. YES NO

44) Certain conditions keep interfering with my personal development. YES NO

45) I seek satisfaction of my own needs and desires first, regardless of the needs and rights of others. YES NO

46) I am usually capable of finding new points of view and successful, sometimes surprising,

2023136901

solutions for problems.

YES: NO:

47) I always try to do what is rational and logically correct. YES NO

48) When I feel like attacking someone physically, I have no inhibitions about doing this at all. YES NO

49) I can relax bodily and mentally only very rarely; most of the time I am very tense. YES NO

50) I am inclined not to be demonstrative when emotional shocks upset me. YES NO

51) I cannot control excitement or stress in my life because this is dependent on the actions of other people. YES NO

52) When I make emotional demands on another person, I require immediate satisfaction. YES NO

53) I am independent in what I do, and do not depend on other people when this works to my disadvantage. YES NO

54) I always try to express my needs and desires in a rational and reasonable manner. YES NO

55) I have no inhibitions in hurting myself physically if I feel like doing so. YES NO

56) I have great difficulties in entering into happy and contended relations with people. YES NO

57) When I feel emotionally let down I tend to be

2023136902

paralysed and inhibited.

**YES**      **NO**

58) I cannot control excitement or stress in my life because this depends on conditions over which I have no control. YES NO

59) I usually find fulfilment in everyday situations which are not subject to ordinary rules, regulations and expectations. YES NO

60) When things don't work out, this does not make me give up, but rather makes me change my way of doing things. YES NO

61) I try to solve my problems in the light of relevant and rational consideration. YES NO

62) I resent all moral obligations because they hamper and inhibit me. YES NO

63) I am helpless when confronted with emotional shocks, depression or anxiety. YES NO

64) When something terrible happens to me, such as the death of a loved one, I am quite unable to express my emotions and desires. YES NO

65) I can express my aims and desires clearly but feel that it is quite impossible to achieve them. YES NO

66) As soon as someone becomes emotionally

2023136903

important for me, I tend to place contradictory demands upon them, such as "Don't ever leave me" or "Get away from me."

YES NO

67) When things lead to harmful results for me, I have no trouble in changing my behaviour to make for success. YES NO

68) I only believe in things which can be proved scientifically and logically. YES NO

69) When it benefits me I have no hesitation in lying and pretending. YES NO

70) I am seldom able to feel enthusiasm for anything. YES NO

2023136304

Scoring Instructions for Short Disease-Proneness Inventory:

Type 1: Add "YES" answers to questions:

1, 8, 15, 22, 29, 36, 43, 50, 57, 64.

Type 2 Add "YES" answers to questions:

2, 9, 16, 23, 30, 37, 44, 51, 58, 65.

Type 3: Add "YES" answers to questions:

3, 10, 17, 24, 31, 38, 45, 52, 59, 66.

Type 4a: Add "YES" answers to questions:

4, 11, 18, 25, 32, 39, 46, 53, 60, 67.

Type 4b: Add "NO" answers to questions:

7, 14, 21, 28, 35, 42, 49, 56, 63, 70.

Type 5: Add "YES" answers to questions:

5, 12, 19, 26, 33, 40, 47, 54, 61, 68.

Type 6: Add "YES" answers to questions:

6, 13, 20, 27, 34, 41, 48, 55, 62, 69.

To decide on TYPE, add 4a and 4b, and divide by 2.  
A person's type is then the one on which he has the highest score. This is the ipsative way of scoring.

Another method is to take all 6 scores into account:

Type 1 is the cancer-prone type;  
" 2 " " coronary heart disease-type;  
" 3 " " alternating reaction type - reasonably healthy;  
" 4 " " autonomous, healthy type;  
" 5 " " rational-antiemotional type; and  
" 6 " " anti-social, egocentric type.

(For further details, see Grossarth-Maticek & Eysenck (1990).

2023136905